

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Emerging small-molecule treatments for multiple... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-245/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-245" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Emerging small-molecule treatments for multiple sclerosis: focus on B cells" />
    
            <meta name="og:title" content="F1000Research Article: Emerging small-molecule treatments for multiple sclerosis: focus on B cells.">
            <meta name="og:description" content="Read the latest article version by Aaron Gregson, Kaitlyn Thompson, Stella E Tsirka, David L Selwood, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="18029">
            <meta name="article-id" content="16495">
            <meta name="dc.title" content="Emerging small-molecule treatments for multiple sclerosis: focus on B cells">
            <meta name="dc.description" content="Multiple sclerosis (MS) is a major cause of disability in young adults. Following an unknown trigger (or triggers), the immune system attacks the myelin sheath surrounding axons, leading to progressive nerve cell death. Antibodies and small-molecule drugs directed against B cells have demonstrated good efficacy in slowing progression of the disease. This review focusses on small-molecule drugs that can affect B-cell biology and may have utility in disease management. The risk genes for MS are examined from the drug target perspective. Existing small-molecule therapies for MS with B-cell actions together with new drugs in development are described. The potential for experimental molecules with B-cell effects is also considered. Small molecules can have diverse actions on B cells and be cytotoxic, anti-inflammatory and anti-viral. The current B cell&ndash;directed therapies often kill B-cell subsets, which can be effective but lead to side effects and toxicity. A deeper understanding of B-cell biology and the effect on MS disease should lead to new drugs with better selectivity, efficacy, and an improved safety profile. Small-molecule drugs, once the patent term has expired, provide a uniquely sustainable form of healthcare.">
            <meta name="dc.subject" content="Multiple sclerosis, MS, B cells, small molecule drugs, sustainable healthcare, ">
            <meta name="dc.creator" content="Gregson, Aaron">
            <meta name="dc.creator" content="Thompson, Kaitlyn">
            <meta name="dc.creator" content="Tsirka, Stella E">
            <meta name="dc.creator" content="Selwood, David L">
            <meta name="dc.date" content="2019/03/01">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.16495.1">
            <meta name="dc.source" content="F1000Research 2019 8:245">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Multiple sclerosis">
            <meta name="prism.keyword" content="MS">
            <meta name="prism.keyword" content="B cells">
            <meta name="prism.keyword" content="small molecule drugs">
            <meta name="prism.keyword" content="sustainable healthcare">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/03/01">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="245">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.16495.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-245">
            <meta name="citation_title" content="Emerging small-molecule treatments for multiple sclerosis: focus on B cells">
            <meta name="citation_abstract" content="Multiple sclerosis (MS) is a major cause of disability in young adults. Following an unknown trigger (or triggers), the immune system attacks the myelin sheath surrounding axons, leading to progressive nerve cell death. Antibodies and small-molecule drugs directed against B cells have demonstrated good efficacy in slowing progression of the disease. This review focusses on small-molecule drugs that can affect B-cell biology and may have utility in disease management. The risk genes for MS are examined from the drug target perspective. Existing small-molecule therapies for MS with B-cell actions together with new drugs in development are described. The potential for experimental molecules with B-cell effects is also considered. Small molecules can have diverse actions on B cells and be cytotoxic, anti-inflammatory and anti-viral. The current B cell&ndash;directed therapies often kill B-cell subsets, which can be effective but lead to side effects and toxicity. A deeper understanding of B-cell biology and the effect on MS disease should lead to new drugs with better selectivity, efficacy, and an improved safety profile. Small-molecule drugs, once the patent term has expired, provide a uniquely sustainable form of healthcare.">
            <meta name="citation_description" content="Multiple sclerosis (MS) is a major cause of disability in young adults. Following an unknown trigger (or triggers), the immune system attacks the myelin sheath surrounding axons, leading to progressive nerve cell death. Antibodies and small-molecule drugs directed against B cells have demonstrated good efficacy in slowing progression of the disease. This review focusses on small-molecule drugs that can affect B-cell biology and may have utility in disease management. The risk genes for MS are examined from the drug target perspective. Existing small-molecule therapies for MS with B-cell actions together with new drugs in development are described. The potential for experimental molecules with B-cell effects is also considered. Small molecules can have diverse actions on B cells and be cytotoxic, anti-inflammatory and anti-viral. The current B cell&ndash;directed therapies often kill B-cell subsets, which can be effective but lead to side effects and toxicity. A deeper understanding of B-cell biology and the effect on MS disease should lead to new drugs with better selectivity, efficacy, and an improved safety profile. Small-molecule drugs, once the patent term has expired, provide a uniquely sustainable form of healthcare.">
            <meta name="citation_keywords" content="Multiple sclerosis, MS, B cells, small molecule drugs, sustainable healthcare, ">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Aaron Gregson">
            <meta name="citation_author_institution" content="The Wolfson Institute for Biomedical Research, University College London, Gower Street, London, WC1E 6BT, UK">
            <meta name="citation_author" content="Kaitlyn Thompson">
            <meta name="citation_author_institution" content="Department of Pharmacological Sciences, Stony Brook University, Stony Brook, New York, 11794, USA">
            <meta name="citation_author" content="Stella E Tsirka">
            <meta name="citation_author_institution" content="Department of Pharmacological Sciences, Stony Brook University, Stony Brook, New York, 11794, USA">
            <meta name="citation_author" content="David L Selwood">
            <meta name="citation_author_institution" content="The Wolfson Institute for Biomedical Research, University College London, Gower Street, London, WC1E 6BT, UK">
            <meta name="citation_publication_date" content="2019/03/01">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="245">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.16495.1">
            <meta name="citation_firstpage" content="245">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-245/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-245.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=18029 /> <input type=hidden id=articleId name=articleId value=16495 /> <input type=hidden id=xmlUrl value="/articles/8-245/v1/xml"/> <input type=hidden id=xmlFileName value="-8-245-v1.xml"> <input type=hidden id=article_uuid value=af060bf1-9b4a-467b-9919-0a4331e93ef6 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Emerging small-molecule treatments for multiple sclerosis: focus on B cells"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.16495.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.16495.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-245"
  },
  "headline": "Emerging small-molecule treatments for multiple sclerosis: focus on B cells",
  "datePublished": "2019-03-01T14:33:14",
  "dateModified": "2019-03-01T14:33:14",
  "author": [
    {
      "@type": "Person",
      "name": "Aaron Gregson"
    },    {
      "@type": "Person",
      "name": "Kaitlyn Thompson"
    },    {
      "@type": "Person",
      "name": "Stella E Tsirka"
    },    {
      "@type": "Person",
      "name": "David L Selwood"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Multiple sclerosis (MS) is a major cause of disability in young adults. Following an unknown trigger (or triggers), the immune system attacks the myelin sheath surrounding axons, leading to progressive nerve cell death. Antibodies and small-molecule drugs directed against B cells have demonstrated good efficacy in slowing progression of the disease. This review focusses on small-molecule drugs that can affect B-cell biology and may have utility in disease management. The risk genes for MS are examined from the drug target perspective. Existing small-molecule therapies for MS with B-cell actions together with new drugs in development are described. The potential for experimental molecules with B-cell effects is also considered. Small molecules can have diverse actions on B cells and be cytotoxic, anti-inflammatory and anti-viral. The current B cell&ndash;directed therapies often kill B-cell subsets, which can be effective but lead to side effects and toxicity. A deeper understanding of B-cell biology and the effect on MS disease should lead to new drugs with better selectivity, efficacy, and an improved safety profile. Small-molecule drugs, once the patent term has expired, provide a uniquely sustainable form of healthcare."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-245",
            "name": "Emerging small-molecule treatments for multiple sclerosis: focus on..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Emerging small-molecule treatments for multiple sclerosis: focus on... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=18029 data-id=16495 data-downloads="" data-views="" data-scholar="10.12688/f1000research.16495.1" data-recommended="" data-doi="10.12688/f1000research.16495.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-245/v1/pdf?article_uuid=af060bf1-9b4a-467b-9919-0a4331e93ef6" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-16495-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-16495-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-16495-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Gregson A, Thompson K, Tsirka SE and Selwood DL. Emerging small-molecule treatments for multiple sclerosis: focus on B cells [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):245 (<a class=new-orange href="https://doi.org/10.12688/f1000research.16495.1" target=_blank>https://doi.org/10.12688/f1000research.16495.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-16495-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=16495 id=track-article-signin-16495 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/16495?target=/articles/8-245">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=18029 /> <input name=articleId type=hidden value=16495 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Emerging small-molecule treatments for multiple sclerosis: focus on B cells</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Aaron Gregson<sup>1</sup>,&nbsp;</span><span class="">Kaitlyn Thompson<sup>2</sup>,&nbsp;</span><span class="">Stella E Tsirka<sup>2</sup>,&nbsp;</span><span class=""><a href="mailto:d.selwood@ucl.ac.uk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>David L Selwood</span></a><a href="https://orcid.org/0000-0002-6817-5064" target=_blank id=author-orcid-3><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-3><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-6817-5064</div><sup>1</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Aaron Gregson<sup>1</sup>,&nbsp;</span><span class="">Kaitlyn Thompson<sup>2</sup>,&nbsp;</span><span class="">Stella E Tsirka<sup>2</sup>,&nbsp;</span><span class=""><a href="mailto:d.selwood@ucl.ac.uk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>David L Selwood</span></a><a href="http://orcid.org/0000-0002-6817-5064" target=_blank id=mauthor-orcid-3><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-3><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-6817-5064</div><sup>1</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 01 Mar 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.16495.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> The Wolfson Institute for Biomedical Research, University College London, Gower Street, London, WC1E 6BT, UK<br/> <sup>2</sup> Department of Pharmacological Sciences, Stony Brook University, Stony Brook, New York, 11794, USA<br/> <p> <div class=margin-bottom> Aaron Gregson <br/> <span>Roles: </span> Data Curation, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Kaitlyn Thompson <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Stella E Tsirka <br/> <span>Roles: </span> Supervision, Writing – Review & Editing </div> <div class=margin-bottom> David L Selwood <br/> <span>Roles: </span> Conceptualization, Formal Analysis, Funding Acquisition, Project Administration, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=8876-44721></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=46531-44722></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Multiple sclerosis (MS) is a major cause of disability in young adults. Following an unknown trigger (or triggers), the immune system attacks the myelin sheath surrounding axons, leading to progressive nerve cell death. Antibodies and small-molecule drugs directed against B cells have demonstrated good efficacy in slowing progression of the disease. This review focusses on small-molecule drugs that can affect B-cell biology and may have utility in disease management. The risk genes for MS are examined from the drug target perspective. Existing small-molecule therapies for MS with B-cell actions together with new drugs in development are described. The potential for experimental molecules with B-cell effects is also considered. Small molecules can have diverse actions on B cells and be cytotoxic, anti-inflammatory and anti-viral. The current B cell–directed therapies often kill B-cell subsets, which can be effective but lead to side effects and toxicity. A deeper understanding of B-cell biology and the effect on MS disease should lead to new drugs with better selectivity, efficacy, and an improved safety profile. Small-molecule drugs, once the patent term has expired, provide a uniquely sustainable form of healthcare. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Multiple sclerosis, MS, B cells, small molecule drugs, sustainable healthcare, </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> David L Selwood (<a href="mailto:d.selwood@ucl.ac.uk">d.selwood@ucl.ac.uk</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> David L Selwood </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> AG was funded by a grant from the National MS Society – Fast Forward group (FF-1602-07939). KT was funded by a PhRMA Foundation Predoctoral fellowship in Pharmacology. <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2019 Gregson A <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Gregson A, Thompson K, Tsirka SE and Selwood DL. Emerging small-molecule treatments for multiple sclerosis: focus on B cells [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):245 (<a href="https://doi.org/10.12688/f1000research.16495.1" target=_blank>https://doi.org/10.12688/f1000research.16495.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 01 Mar 2019, <b>8</b>(F1000 Faculty Rev):245 (<a href="https://doi.org/10.12688/f1000research.16495.1" target=_blank>https://doi.org/10.12688/f1000research.16495.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 01 Mar 2019, <b>8</b>(F1000 Faculty Rev):245 (<a href="https://doi.org/10.12688/f1000research.16495.1" target=_blank>https://doi.org/10.12688/f1000research.16495.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d5420e192>Introduction</h2><p class="" id=d5420e195>Multiple sclerosis (MS) affects over two million people worldwide (National Multiple Sclerosis Society, <a target=xrefwindow href="https://www.nationalmssociety.org/" id=d5420e197>https://www.nationalmssociety.org/</a>). The disease is characterised by an initial autoimmune-driven, inflammatory phase followed by immune-mediated attack on the myelin surrounding nerve axons. Focal cortical lesions may develop in distinct locations. Eventually, the ensuing damage results in progressive nerve loss and increasing disability evident as disrupted motor function, visual disturbances, and bladder problems<sup><a href="#ref-1">1</a></sup>. As disease onset is often reported in young adults, its course can affect people for most of their adult lives. MS is considered to present in several forms: relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS) and progressive-relapsing MS (PRMS). Diagnosis of the disease is complex; there is no single test for MS, and multiple criteria, including magnetic resonance imaging (MRI) scans are used<sup><a href="#ref-2">2</a></sup>.</p><p class="" id=d5420e209>The causes of the disease are multifactorial, with infectious, genetic and environmental factors, such as lack of sunlight (through vitamin D), playing a role (<a href="#f1">Figure 1</a>)<sup><a href="#ref-3">3</a></sup>. Large genome-wide association studies (GWASs) have gradually allowed the risk genes associated with MS to be elucidated. Up to now, genetics alone has not proven useful in diagnosis<sup><a href="#ref-4">4</a></sup>, but the identified risk genes have been informative about the mechanism and contributors to the disease and may be of aid in predicting severity<sup><a href="#ref-5">5</a></sup>. Among the more than 200 risk genes, most with a link to immune function, identified as susceptibility factors, the strongest associations are with the <i>HLA-DRB1</i> (human leucocyte antigen) locus in the major histocompatibility complex (MHC)<sup><a href="#ref-4">4</a></sup>.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_figure1.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_figure1.gif"></a><div class=caption><h3>Figure 1. Causes and progression of multiple sclerosis (MS).</h3><p id=d5420e245>Several studies now indicate that Epstein–Barr virus infection is necessary (but not causal) for MS to develop. Genetic factors may explain 50% of MS susceptibility whereas environmental factors together with unknowns may combine to trigger immune activation and the subsequent destruction of myelin and oligodendrocytes. This eventually leads to axonal damage and nerve cell death resulting in disability. HERV, human endogenous retrovirus.</p></div></div><p class="" id=d5420e252>Although multiple types of immune cells have been implicated in the pathology of MS [4], the role of B cells has recently come to the fore<sup><a href="#ref-6">6</a></sup>; notable clinical successes for agents which target B cells, such as CD20-targeted antibodies, rituximab, ocrelizumab and ofatumumab, are reported. In addition, an analysis of agents used to treat MS indicated that activity against a specific subset of B cells, the CD19<sup>+</sup>CD27<sup>+</sup> memory B cells, correlated with clinical efficacy<sup><a href="#ref-7">7</a>–<a href="#ref-9">9</a></sup>.</p><p class="" id=d5420e273>Despite this strong driver to develop new B cell–directed therapies, the current most popular animal model used to study MS-like pathologies, particularly inflammation and neurodegeneration—experimental autoimmune encephalomyelitis (EAE) in mice—does not allow an assessment of a causative role for B-cell involvement, complicating further development<sup><a href="#ref-10">10</a></sup>. A review of animal models unsurprisingly points to primate models, such as the marmoset, as the most representative of the human disease<sup><a href="#ref-11">11</a></sup>.</p><p class="" id=d5420e284>The recent focus on how B cells contribute to MS pathology also renews interest in the role of Epstein–Barr virus (EBV) infection in the aetiology of the disease. EBV is present in a high percentage of the human population, preferentially infects B cells, and establishes a lifelong infection in memory B cells<sup><a href="#ref-12">12</a></sup>. The impact of EBV in MS is controversial; some convincing recent studies indicate that infection with EBV may underlie the development of MS. Over 99% of people with MS are infected with EBV, and it has been argued that methodological differences may account for the small number of EBV-negatives<sup><a href="#ref-13">13</a></sup>. Although the effect of EBV has been extensively investigated in B cells and is also present in astrocytes and microglia of people with MS (pwMS)<sup><a href="#ref-14">14</a></sup>, the impact of EBV infection in the brain is relatively little studied. Thus, the extent and mechanism of the EBV effect remains somewhat obscure and more research is needed in this area. Numerous mechanistic links between EBV infection and MS pathology have been noted<sup><a href="#ref-15">15</a></sup>. Some of the most persuasive arguments are summarised in <a href="#T1">Table 1</a><sup><a href="#ref-16">16</a>–<a href="#ref-26">26</a></sup>.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Supporting and opposing arguments for EBV involvement in MS.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d5420e323 class=n-a></a><thead><a name=d5420e325 class=n-a></a><tr><a name=d5420e327 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d5420e329 class=n-a></a>Supporting arguments</th><th align=left colspan=1 rowspan=1><a name=d5420e332 class=n-a></a>Opposing arguments (partly from <a href="#ref-16">16</a>)</th></tr></thead><tbody><a name=d5420e340 class=n-a></a><tr><a name=d5420e342 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e344 class=n-a></a>•&nbsp;&nbsp;Epstein–Barr virus (EBV) infects and is latent in memory B cells, the same cell<br class=br>type shown to be critical in multiple sclerosis (MS) by successful CD20 antibody<br class=br>and cladribine treatment.<br class=br>•&nbsp;&nbsp;Genome-wide association studies (GWASs) have identified a correlation between<br class=br>anti-EBV nuclear antigen-1 (EBNA-1) IgG titres and MS<sup><a href="#ref-27">27</a></sup>. Human leucocyte antigen<br class=br>(HLA) single-nucleotide polymorphisms showed the strongest correlation with two<br class=br>other genes: <i>EVI5</i> and <i>EOMES</i><sup><a href="#ref-28">28</a></sup>.<br class=br>•&nbsp;&nbsp;GWAS analysis reveals genetic overlap between susceptibilities to Hodgkin’s<br class=br>lymphoma (caused by EBV) and MS<sup><a href="#ref-29">29</a></sup>.<br class=br>•&nbsp;&nbsp;In B cells transformed into immortalised lymphoblasts by EBV infection, the<br class=br>vitamin D receptor (VDR) (nuclear receptor) interacts with the EBV nuclear protein<br class=br>EBNA3. This results in inhibition of VDR-promoted gene expression and provides a<br class=br>mechanistic link between vitamin D, EBV and MS<sup><a href="#ref-30">30</a></sup>.<br class=br>•&nbsp;&nbsp;EBV uses HLA DRB1 and HLA DRQ allelic variants as entry co-receptors. This<br class=br>is widely assumed to have immune consequences. A link between HLA variants<br class=br>and infectivity by EBV has not yet been made, although this has been proposed for<br class=br>rheumatoid arthritis<sup><a href="#ref-31">31</a></sup>.<br class=br>•&nbsp;&nbsp;Infectious mononucleosis is caused by EBV infection and is associated with an<br class=br>increased risk of MS<sup><a href="#ref-32">32</a></sup>.<br class=br>•&nbsp;&nbsp;EBV is found to activate the human endogenous retroviruses HERV-W/MSRV/<br class=br>Syncytin-1 (human endogenous retrovirus type W/multiple sclerosis–associated<br class=br>retrovirus/Syncytin-1) in blood and brain cells taken from people with MS (pwMS).<br class=br>MSRV specifically has been reported to correlate with progression to MS<sup><a href="#ref-33">33</a></sup> and with<br class=br>infectious mononucleosis.<br class=br>•&nbsp;&nbsp;A virus closely related to EBV, the γ1-herpesvirus CalHV3, infects marmosets,<br class=br>is resident in memory B cells, and is implicated in the marmoset experimental<br class=br>autoimmune encephalomyelitis model of experimental MS<sup><a href="#ref-34">34</a></sup>.</td><td colspan=1 rowspan=1 valign=top><a name=d5420e442 class=n-a></a>•&nbsp;&nbsp;Seropositivity for pwMS infected with EBV does<br class=br>not reach 100%, especially for children with early-<br class=br>onset MS<sup><a href="#ref-35">35</a></sup>. The high background of people infected<br class=br>with EBV clouds the interpretation.<br class=br>•&nbsp;&nbsp;Serum EBNA-1 antibodies are associated with<br class=br>MS, but no target has been found, and antibody<br class=br>levels are not associated with disease activity<sup><a href="#ref-36">36</a></sup>.<br class=br>•&nbsp;&nbsp;EBV seroconversion may just be a hygiene<br class=br>marker, and other parasites could be responsible for<br class=br>the development of MS<sup><a href="#ref-37">37</a></sup>.</td></tr></tbody></table></div><p class="" id=d5420e481>Other infections such as human herpes virus 6<sup><a href="#ref-16">16</a></sup> and pinworms<sup><a href="#ref-17">17</a></sup> have also been implicated in MS.</p><p class="" id=d5420e492>The developing picture for MS is of a disease caused by the interaction of multiple risk factors (<a href="#f1">Figure 1</a>), one being EBV infection. EBV could initiate changes in infected cells that lead to immune activation and a pro-inflammatory state. This alone is not sufficient to cause MS, but genetic and environmental factors then can be activated, interact and trigger the disease. Treatments defined as disease-modifying therapies (DMTs) are usually immune-modulators, other drugs treat symptoms such as limb spasticity, bladder problems, or pain. There are as yet no therapies approved to treat neurodegeneration<sup><a href="#ref-18">18</a></sup>. New immunomodulators have transformed the treatment of RRMS; at least 16 drugs are now licensed by the US Food and Drug Administration (FDA) (<a target=xrefwindow href="https://www.nationalmssociety.org/Treating-MS/Medications" id=d5420e501>https://www.nationalmssociety.org/Treating-MS/Medications</a>) and these have generated a $20 billion market<sup><a href="#ref-19">19</a></sup>. Although the number and severity of relapses have been reduced, neurological damage still occurs from onset and the disease often continues to the progressive form. Furthermore, those patients with diagnosed PPMS have historically had no DMTs available to them.</p><p class="" id=d5420e509>Notably, the first drug indicated for PPMS, the anti-CD20 antibody ocrelizumab (Ocrevus<sup>®</sup>), was approved by the FDA in 2017<sup><a href="#ref-20">20</a></sup>. Ocrelizumab and other anti-CD20 therapies rapidly deplete circulating B cells. Their effectiveness in patients with PPMS and RRMS points to an important role for B cells in multiple MS forms. In a phase 3 trial, ocrelizumab was associated with lessened disease activity and progression in patients with RRMS compared with interferon beta-1a<sup><a href="#ref-21">21</a></sup>. Along the same lines, a 2018 study compared rituximab (an anti-CD20 antibody approved for other conditions) as an initial treatment for patients with RRMS and found its clinical efficacy to be notably superior to that of several other first-line DMTs, including dimethyl fumarate, natalizumab and fingolimod<sup><a href="#ref-22">22</a></sup>.</p><p class="" id=d5420e528>These agents have been paradigm-changing in providing the first DMT for patients with PPMS, a potentially more effective first line of treatment for RRMS, as well as turning the therapeutic focus from T cells (previously thought of as the main autoimmune effector cell in MS) to B cells. The remarkable clinical evidence with these drugs clearly illustrates that B cells play a central role in MS pathogenesis. Although this is exciting, there does remain a critical need for improvements to existing treatments in RRMS and new stand-alone treatments for SPMS and PPMS that serve to minimise adverse effects and the burden of high expense.</p><p class="" id=d5420e531>This review focusses on small-molecule approaches to immune-related MS therapy, covering agents on the market, in clinical trials, and some new research approaches. We specifically emphasise potential B cell–targeted therapies and the effects of already-available therapies on the B-cell population because of the recent notable success of ocrelizumab and other anti-CD20 antibodies.</p><p class="" id=d5420e534>Small molecules have unique and beneficial properties as therapies. The advantages include the ability to access intracellular targets and penetrate the central nervous system (CNS), low cost of manufacture, ease of administration, and the option to withdraw therapy rapidly. The primary disadvantage of small molecules is their potential lack of cellular specificity. The low cost of manufacture of small molecules compared with biological or cell-based therapies is often overlooked, but with increasing healthcare demands, a path to sustainable and affordable treatments is required for the future.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5420e540>Identifying the genes and proteins key to multiple sclerosis pathophysiology as potential drug targets</h2><p class="" id=d5420e543>Large GWASs have identified multiple genes associated with MS (reviewed in <a href="#ref-4">4</a>). Of note, HLA-DRB1*15:01 has an odds ratio (OR) of about 3.5; OR is the ratio of people with a proposed disease-specific allele to those who do not have the disease, where 1 is no association and more than 1 indicates an increased risk. In total, 31 HLA genes have been found<sup><a href="#ref-23">23</a></sup>. Non-HLA genes have also been indicated to contribute to genetic susceptibility; in particular, a very recent communication by the International Multiple Sclerosis Genetics Consortium (IMSGC) (<a href="#ST1">Supplementary Table 1, Table 1</a>) lists over 200 genes, showing the non-HLA-related genes<sup><a href="#ref-23">23</a></sup>.</p><p class="" id=d5420e560>The study builds on an earlier publication by the IMSGC detailing 97 non-HLA genes<sup><a href="#ref-24">24</a></sup>. The later gene set does not cover all of the earlier genes. For this review, we used the UniprotKB curated database to provide high-quality information on the gene sets (<a href="#ST1">Supplementary Table, Table 1</a>) and use this information to relate the genes to specific cell types.</p><div class=section><a name=d5420e570 class=n-a></a><h3 class=section-title>B cells</h3><p class="" id=d5420e575>In the 2018 IMSGC set, the UniprotKB database indicates that 31 genes either are highly expressed in or have some B-cell function noted (<a href="#ST1">Supplementary Table, Table 2</a>). Only two of these genes appear to have been drugged: <i>CTLA4</i> (ipilimumab) and the cannabinoid receptor 2, <i>CNR2</i> (cannabidiol).</p></div><div class=section><a name=d5420e588 class=n-a></a><h3 class=section-title>Epstein–Barr virus</h3><p class="" id=d5420e593>In the IMSGC gene set from 2013, four genes (<i>PXT1</i>, <i>ZMIZ1</i>, <i>EOMES</i> and <i>TRAF3</i>) are linked to EBV. Further investigations have identified 47 EBV genes from transcriptomes of B cells and EBV cells infected at Latency III (LCLs) associated with MS<sup><a href="#ref-25">25</a></sup>. This study highlights the EBV-encoded cell surface protein LMP1 and its signalling pathway as a potential target for MS.</p></div><div class=section><a name=d5420e614 class=n-a></a><h3 class=section-title>Vitamin D</h3><p class="" id=d5420e619>Two well-recognised MS susceptibility genes—<i>CYP27B1</i> and <i>CYP24A1</i>—control metabolism of vitamin D (1,25-dihydroxyvitamin D3) for its receptor (VDR)<sup><a href="#ref-3">3</a></sup>. Lack of 1,25-dihydroxyvitamin D3 is associated with several immune diseases. The synthesis of 1,25-dihydroxyvitamin D3 is enhanced by sunlight and thus provides a mechanistic basis for the observed latitude dependence of MS. Further studies highlighted <i>ZMIZ1</i>, <i>ZMIZ1</i>-<i>AS1</i> (AS stands for anti-sense, signifying that the single-nucleotide polymorphism is on the anti-sense strand) and <i>IRF8</i>. The VDR influences the expression and function of many other genes. <i>TAGAP</i> (T-cell activation RhoGTPase activating protein, which has a role in Th17 differentiation) and <i>IL2RA</i> were also identified by the GWASs and as 1,25-dihydroxyvitamin D3 target genes in a study on CD4<sup>+</sup> T cells<sup><a href="#ref-26">26</a></sup>.</p><p class="" id=d5420e658>In the 2017 IMSGC report on the 200-plus gene set, the authors acknowledge that CNS genes may be under-represented. They partly address this by conducting an RNA-Seq study on cortex material to provide a data set more representative of CNS genes altered by the disease pathology. Only two of the RNA-Seq genes are represented in the 2013 IMSGC GWAS set: <i>GALC</i> and <i>RGS14</i>. In the 2017 IMSGC set, <i>RGS14</i> and <i>PVR</i> are common genes.</p></div><div class=section><a name=d5420e674 class=n-a></a><h3 class=section-title>Astrocytes</h3><p class="" id=d5420e679>Five genes in the GWAS sets are expressed in or linked to astrocyte function (<i>CLEC16A</i>, <i>IL22RA2</i>, <i>TNFRSF1A</i>, <i>CYP24A1</i> and <i>PHGDH</i>). Also, seven genes from these sets have a link to neurodegeneration excluding that of MS (<i>GALC</i>, <i>PITPNM2</i>, <i>DIKKL1</i>, <i>SLC2A4RG</i>, <i>FCRL1</i> and <i>PHDGH</i>). One other gene links to neurodegeneration (<i>NPEPPS</i>); this gene codes for an aminopeptidase which may regulate neuropeptide activity and tau levels<sup><a href="#ref-38">38</a>,<a href="#ref-39">39</a></sup>.</p></div><div class=section><a name=d5420e728 class=n-a></a><h3 class=section-title>Oligodendrocytes</h3><p class="" id=d5420e733>Three genes—<i>OLIG3</i> (oligodendrocyte transcription factor), <i>ZNF365</i> (DISC1-binding zinc finger protein) and <i>BCAS</i>—are key to oligodendrocyte function. <i>BCAS</i> was recently reported as being present in MS lesions<sup><a href="#ref-40">40</a></sup>; mice lacking this gene display hypomyelination<sup><a href="#ref-41">41</a></sup>. The interaction database STRING links <i>BCAS1</i> to <i>QKI</i>, a gene thought to play a major role in oligodendrocyte differentiation and myelination<sup><a href="#ref-42">42</a></sup>.</p></div><div class=section><a name=d5420e768 class=n-a></a><h3 class=section-title>Intracellular organelles</h3><p class="" id=d5420e773> <b> <i>Mitochondria.</i> </b> Mitochondrial dysfunction is thought to play a role in neurodegeneration<sup><a href="#ref-43">43</a></sup>. In the GWAS and RNA-Seq studies, 23 genes, including the <i>CYP24A1</i> vitamin D susceptibility gene, link to mitochondria. Several others are linked to oxidation reduction and the electron transport chain: <i>COXM1</i>, <i>WWOX</i>, <i>PRDX5</i>, <i>IPYR2</i>, <i>CYB</i> and <i>ALDH2</i> (<a href="#ST1">Supplementary Table, Table 6</a>). Previous studies highlight the electron transport chain as a dysregulated pathway in MS lesions, although the differently expressed genes listed in these studies (<a href="#ST1">Supplementary Table, Table 7</a>) differ from those reported in the GWAS studies. Only two genes—<i>CYTB</i> (cytochrome b [complex III subunit 3, mitochondrially encoded]) and <i>CASQ1</i> (calsequestrin-1 [calmitine])—were reported by both the IMSG RNA-Seq 2017 study and the 2012 study. Cytochrome b is, of course, intimately involved in the generation of the proton gradient that ultimately produces ATP. Defects in the electron transport chain are also linked to reactive oxygen species (ROS) generation. Calsequestrin-1 is a calcium binding protein in muscle. Deletion of the gene in mice or mutations in the human gene or both cause muscle atrophy and mitochondrial dysfunction<sup><a href="#ref-44">44</a></sup>. Defects in this pathway underscore the rationale for anti-oxidant approaches, such as Nrf-2 activation (dimethylfumarate)<sup><a href="#ref-45">45</a></sup> or permeability pore inhibition via mitochondrial cyclophilin D<sup><a href="#ref-46">46</a></sup>.</p><p class="" id=d5420e833>The picture is broadly reflective of MS pathology. However, very few of these genes have been pursued as drug targets and even fewer taken into clinical trials. A recent study attempted to concatenate all of the GWAS data and has produced two more restricted gene lists for pwMS versus control and pwMS undergoing treatment. This study identified interferon-gamma signalling as the major pathway involved<sup><a href="#ref-47">47</a></sup>. Importantly, the multiple genes associated with B-cell function/dysfunction and EBV support a role in MS pathology.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5420e844>Immune cells: small-molecule drugs</h2><p class="" id=d5420e847>In <a href="#T2">Table 2</a>, a method of assessing the likely CNS penetration of a compound is given where there are no published data. The scoring method used is the multiparameter optimisation method<sup><a href="#ref-48">48</a></sup>.</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Multiple sclerosis (MS)-relevant small molecules with activity against immune cells.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d5420e868 class=n-a></a><thead><a name=d5420e870 class=n-a></a><tr><a name=d5420e872 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d5420e874 class=n-a></a>Name</th><th align=left colspan=1 rowspan=1><a name=d5420e877 class=n-a></a>Structure</th><th align=left colspan=1 rowspan=1><a name=d5420e880 class=n-a></a>Target/Mode of action</th><th align=left colspan=1 rowspan=1><a name=d5420e883 class=n-a></a>Relevance to MS</th><th align=left colspan=1 rowspan=1><a name=d5420e886 class=n-a></a>Central nervous system penetration</th></tr></thead><tbody><a name=d5420e891 class=n-a></a><tr><a name=d5420e893 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e895 class=n-a></a>Bortezomib</td><td colspan=1 rowspan=1 valign=top><a name=d5420e898 class=n-a></a> <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T1.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T1.gif"></a> </td><td colspan=1 rowspan=1 valign=top><a name=d5420e903 class=n-a></a>Proteasome</td><td colspan=1 rowspan=1 valign=top><a name=d5420e906 class=n-a></a>No studies reported</td><td colspan=1 rowspan=1 valign=top><a name=d5420e909 class=n-a></a>Does not cross the blood–brain<br class=br>barrier (BBB)<sup><a href="#ref-68">68</a></sup><br class=br><sup><a href="#TFN1">a</a></sup>Multiparameter optimisation<br class=br>(MPO) = 2.8</td></tr><tr><a name=d5420e925 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e927 class=n-a></a>Carfilzomib</td><td colspan=1 rowspan=1 valign=top><a name=d5420e930 class=n-a></a> <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T2.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T2.gif"></a> </td><td colspan=1 rowspan=1 valign=top><a name=d5420e935 class=n-a></a>Proteasome</td><td colspan=1 rowspan=1 valign=top><a name=d5420e938 class=n-a></a>No studies reported</td><td colspan=1 rowspan=1 valign=top><a name=d5420e941 class=n-a></a>Does not cross the BBB<sup><a href="#ref-69">69</a></sup><br class=br>MPO = 1.0</td></tr><tr><a name=d5420e950 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e952 class=n-a></a>Ibrutinib</td><td colspan=1 rowspan=1 valign=top><a name=d5420e955 class=n-a></a> <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T3.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T3.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T3.gif"></a> </td><td colspan=1 rowspan=1 valign=top><a name=d5420e960 class=n-a></a>B-cell progenitor (Bruton) tyrosine<br class=br>kinase is highly expressed in<br class=br>immature B cells, monocytes and<br class=br>natural killer (NK) cells but not<br class=br>T cells.</td><td colspan=1 rowspan=1 valign=top><a name=d5420e971 class=n-a></a>No development reported </td><td colspan=1 rowspan=1 valign=top><a name=d5420e974 class=n-a></a>In mice, Ibrutinib rapidly crosses<br class=br>the BBB (in 0.29 hours). Brain-to-<br class=br>plasma ratio average for ibrutinib<br class=br>was found to reach 0.7<sup><a href="#ref-70">70</a></sup>.<br class=br>MPO = 2.5</td></tr><tr><a name=d5420e990 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e992 class=n-a></a>Evobrutinib</td><td colspan=1 rowspan=1 valign=top><a name=d5420e995 class=n-a></a> <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T4.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T4.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T4.gif"></a> </td><td colspan=1 rowspan=1 valign=top><a name=d5420e1000 class=n-a></a>B-cell progenitor (Bruton) tyrosine<br class=br>kinase</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1005 class=n-a></a>Positive phase IIB results were reported in MS<br class=br>(7 March 2018).</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1010 class=n-a></a>Capability to pass the BBB has not<br class=br>been assessed.<br class=br>MPO = 2.0</td></tr><tr><a name=d5420e1018 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e1020 class=n-a></a>PRN2246<br class=br>Possible structure<br class=br>shown</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1027 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T5.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T5.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T5.gif"></a></td><td colspan=1 rowspan=1 valign=top><a name=d5420e1030 class=n-a></a>B-cell progenitor (Bruton) tyrosine<br class=br>kinase</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1035 class=n-a></a>Sanofi is developing a Principia MS candidate<sup><a href="#ref-71">71</a></sup>.</td><td colspan=1 rowspan=1><a name=d5420e1042 class=n-a></a>A recent press release confirmed<br class=br>that PRN2246 crosses the BBB in<br class=br>humans and achieves therapeutic<br class=br>levels in the cerebral spinal fluid<sup><a href="#ref-72">72</a></sup>.<br class=br>MPO = 3.4</td></tr><tr><a name=d5420e1059 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e1061 class=n-a></a>Idelalisib</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1064 class=n-a></a> <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T6.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T6.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T6.gif"></a> </td><td colspan=1 rowspan=1 valign=top><a name=d5420e1069 class=n-a></a>PI3Kδ is widely expressed in<br class=br>immune cells.</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1074 class=n-a></a>No development reported</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1077 class=n-a></a>Does not cross a healthy BBB<sup><a href="#ref-73">73</a></sup><br class=br>MPO = 2.9</td></tr><tr><a name=d5420e1086 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e1088 class=n-a></a>CP-25 paeoniflorin-6′-<br class=br>O-benzene sulfonate</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1093 class=n-a></a> <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T7.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T7.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T7.gif"></a> </td><td colspan=1 rowspan=1 valign=top><a name=d5420e1098 class=n-a></a>BAFF</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1101 class=n-a></a>No development reported</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1104 class=n-a></a>A recent tissue distribution and<br class=br>excretion study in rats suggests<br class=br>that CP-25 can pass through the<br class=br>BBB with significant differences<br class=br>seen between rat genders<sup><a href="#ref-74">74</a></sup>.<br class=br>MPO = 2.0</td></tr><tr><a name=d5420e1123 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e1125 class=n-a></a>Cladribine</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1128 class=n-a></a> <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T8.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T8.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T8.gif"></a> </td><td colspan=1 rowspan=1 valign=top><a name=d5420e1133 class=n-a></a>Adenosine deaminase</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1136 class=n-a></a>Positive results in phase III CLARITY study<sup><a href="#ref-75">75</a>–<a href="#ref-77">77</a></sup><br class=br>Positive results in phase III CLARITY extension<br class=br>study<sup><a href="#ref-2">2</a></sup><br class=br>Positive results in phase III ORACLE MS study<sup><a href="#ref-78">78</a></sup>,<sup><a href="#ref-79">79</a></sup><br class=br>Positive results in phase II ONWARD study<br class=br>adding oral cladribine to interferon beta-1a<br class=br>treatment<sup><a href="#ref-80">80</a></sup><br class=br>Long-term follow-up of safety currently active<br class=br>(PREMIERE)<br class=br>US Food and Drug Administration (FDA)<br class=br>accepted New Drug Application resubmission in<br class=br>July 2018<br class=br>(Melao, FDA to Review EMD Serono’s<br class=br>New Request for Approval of Cladribine<br class=br>for Treating Relapsing MS, 2018 <a target=xrefwindow href="https://multiplesclerosisnewstoday.com/2018/07/31/fda-accepts-resubmitted-nda-cladribine-tablets-treatment-relapsing-ms/" id=d5420e1188>https://</a><br class=br><a target=xrefwindow href="https://multiplesclerosisnewstoday.com/2018/07/31/fda-accepts-resubmitted-nda-cladribine-tablets-treatment-relapsing-ms/" id=d5420e1191>multiplesclerosisnewstoday.com/2018/07/31/</a><br class=br><a target=xrefwindow href="https://multiplesclerosisnewstoday.com/2018/07/31/fda-accepts-resubmitted-nda-cladribine-tablets-treatment-relapsing-ms/" id=d5420e1194>fda-accepts-resubmitted-nda-cladribine-tablets-</a><br class=br><a target=xrefwindow href="https://multiplesclerosisnewstoday.com/2018/07/31/fda-accepts-resubmitted-nda-cladribine-tablets-treatment-relapsing-ms/" id=d5420e1197>treatment-relapsing-ms/"&gt;https://multiplesclerosisnewstoday.com/2018/07/31/fda-accepts-resubmitted-nda-cladribine-tablets-treatment-relapsing-ms/</a>).</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1201 class=n-a></a>Cladribine concentration in the<br class=br>cerebrospinal fluid (CSF) is about<br class=br>25% of the plasma concentration<br class=br>at dose rates between 0.17 and<br class=br>2.5 mg/m<sup>2</sup> per hour intravenously<br class=br>in patients without known<br class=br>meningeal disease<sup><a href="#ref-54">54</a></sup>.<br class=br>MPO = 3.3</td></tr><tr><a name=d5420e1227 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e1229 class=n-a></a>Maribavir</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1232 class=n-a></a> <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T9.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T9.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T9.gif"></a> </td><td colspan=1 rowspan=1 valign=top><a name=d5420e1237 class=n-a></a>Potential Epstein–Barr virus (EBV)<br class=br>treatment</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1242 class=n-a></a>No studies reported</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1245 class=n-a></a>Maribavir does not cross<br class=br>the BBB in rats. In monkeys,<br class=br>maribavir levels in the brain,<br class=br>CSF and vitreous humour<br class=br>range from 4-20%, 1-2% and<br class=br>&lt;1% of corresponding plasma<br class=br>concentration, respectively<sup><a href="#ref-81">81</a></sup>.<br class=br>MPO = 3.4</td></tr><tr><a name=d5420e1268 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e1270 class=n-a></a>KAY-2-41</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1273 class=n-a></a> <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T10.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T10.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T10.gif"></a> </td><td colspan=1 rowspan=1 valign=top><a name=d5420e1278 class=n-a></a>DNA polymerase in EBV-infected<br class=br>cells</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1283 class=n-a></a>No studies reported</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1286 class=n-a></a>Capability to pass the BBB has not<br class=br>been assessed.<br class=br>MPO = 4.2</td></tr><tr><a name=d5420e1294 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e1296 class=n-a></a>KAY-39-149</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1299 class=n-a></a> <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T11.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T11.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T11.gif"></a> </td><td colspan=1 rowspan=1 valign=top><a name=d5420e1304 class=n-a></a>DNA polymerase in EBV-infected<br class=br>cells</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1309 class=n-a></a>No studies reported</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1312 class=n-a></a>Capability to pass the BBB has not<br class=br>been assessed.<br class=br>MPO = 3.2</td></tr><tr><a name=d5420e1321 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e1323 class=n-a></a>HPMP-5-azaC</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1326 class=n-a></a> <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T12.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T12.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T12.gif"></a> </td><td colspan=1 rowspan=1 valign=top><a name=d5420e1331 class=n-a></a>DNA polymerase</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1334 class=n-a></a>No studies reported</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1337 class=n-a></a>Capability to pass the BBB has not<br class=br>been assessed.<br class=br>MPO = 3.0</td></tr><tr><a name=d5420e1345 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e1347 class=n-a></a>Glatiramer acetate<br class=br>(random peptides of<br class=br>the following amino<br class=br>acids <i>L-Glutamic Acid</i><br class=br><i>peptide with L-Alanine</i><br class=br><i>L-Lysine L-Tyrosine</i><br class=br><i>Acetate Salt</i>)</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1369 class=n-a></a></td><td colspan=1 rowspan=1 valign=top><a name=d5420e1371 class=n-a></a>Alters antigen-presenting cell (APC)<br class=br>function, potentially B cells</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1376 class=n-a></a>FDA approved in 1997 as Copaxone for<br class=br>relapsing-remitting MS (RRMS) and clinically<br class=br>isolated syndrome (CIS).<br class=br>Two generic forms were approved in 2017.</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1385 class=n-a></a>Owing to its high polarity and<br class=br>hydrophilic nature, glatiramer acetate<br class=br>does not penetrate the BBB<sup><a href="#ref-82">82</a></sup>.</td></tr><tr><a name=d5420e1397 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e1399 class=n-a></a>Dimethyl fumarate<br class=br>(<i>Tecfidera</i>)</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1407 class=n-a></a> <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T14.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T14.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T14.gif"></a> </td><td colspan=1 rowspan=1 valign=top><a name=d5420e1412 class=n-a></a>Antigen-presenting and cytokine-<br class=br>producing functions of B cells</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1417 class=n-a></a>FDA approved in 2013 for RRMS</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1420 class=n-a></a>Metabolite monomethyl<br class=br>fumarate (MMF), the primary<br class=br>metabolite observed after oral<br class=br>dimethylfumarate (DMF) dosing,<br class=br>crossed the BBB. MMF exposure<br class=br>was measured 30 min after a single<br class=br>oral dose of DMF (100 mg/kg) in wild-<br class=br>type mice. The highest concentrations<br class=br>were in plasma (307.2–54.79 µM),<br class=br>and exposures of about 100 µM were<br class=br>observed between peripheral organs<br class=br>and brain<sup><a href="#ref-83">83</a></sup>.<br class=br>MPO = 5.0</td></tr><tr><a name=d5420e1454 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e1456 class=n-a></a>Fostamatinib</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1459 class=n-a></a> <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T15.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T15.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T15.gif"></a> </td><td colspan=1 rowspan=1 valign=top><a name=d5420e1464 class=n-a></a>Protein tyrosine kinase syk (spleen<br class=br>tyrosine kinase)</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1469 class=n-a></a>No development reported</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1472 class=n-a></a>Capability to pass the BBB has not<br class=br>been assessed.<br class=br>MPO = 2.4</td></tr><tr><a name=d5420e1480 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e1482 class=n-a></a>Fingolimod<br class=br>Requires<br class=br>phosphorylation for<br class=br>activation</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1491 class=n-a></a> <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T16.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T16.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T16.gif"></a> </td><td colspan=1 rowspan=1 valign=top><a name=d5420e1496 class=n-a></a>Sphingosine-1-phosphate receptor<br class=br>(S1P<sub>1/3/4/5</sub>)</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1504 class=n-a></a>FDA approved in 2011 for RRMS<br class=br>Approved for children and adolescents with<br class=br>RRMS in 2018.<br class=br>Phase IV study comparing fingolimod with<br class=br>dimethyl fumarate is currently recruiting.</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1515 class=n-a></a>FTY720 has been shown to<br class=br>cross the BBB in rats, dogs and<br class=br>humans. Tissue-to-blood partition<br class=br>coefficient values in rats were 22.9<br class=br>for lymph nodes, 27.1 for brain,<br class=br>and 15.7 for thymus.<br class=br>MPO = 2.8</td></tr><tr><a name=d5420e1532 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e1534 class=n-a></a>Amiselimod</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1537 class=n-a></a> <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T17.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T17.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T17.gif"></a> </td><td colspan=1 rowspan=1 valign=top><a name=d5420e1542 class=n-a></a>S1P<sub>1</sub></td><td colspan=1 rowspan=1 valign=top><a name=d5420e1547 class=n-a></a>Positive results in phase II MOMENTUM study for<br class=br>RRMS<sup><a href="#ref-84">84</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d5420e1555 class=n-a></a>Capability to pass the BBB has not<br class=br>been assessed.<br class=br>MPO = 2.8</td></tr><tr><a name=d5420e1564 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e1566 class=n-a></a>Siponimod</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1569 class=n-a></a> <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T18.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T18.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T18.gif"></a> </td><td colspan=1 rowspan=1 valign=top><a name=d5420e1574 class=n-a></a>S1P<sub>1</sub>/ S1P<sub>5</sub></td><td colspan=1 rowspan=1 valign=top><a name=d5420e1582 class=n-a></a>Positive results in phase II trial for RRMS<sup><a href="#ref-84">84</a></sup><br class=br>Mechanistic phase III trial completed<br class=br>Efficacy and safety phase III EXPAND trial is<br class=br>currently active for patients with secondary<br class=br>progressive MS (SPMS).</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1596 class=n-a></a>Brain distribution was examined<br class=br>using an iodine-labelled analogue<br class=br>of siponimod, [<sup>123</sup>I]MS565.<br class=br>Intravenous injections gave<br class=br>concentrations in the rhesus<br class=br>monkey brain of 0.008 to 0.014<br class=br>%ID/mL at around 24 hours<sup><a href="#ref-85">85</a></sup>.<br class=br>MPO = 2.3</td></tr><tr><a name=d5420e1622 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e1624 class=n-a></a>Ozanimod</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1627 class=n-a></a> <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T19.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T19.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T19.gif"></a> </td><td colspan=1 rowspan=1 valign=top><a name=d5420e1632 class=n-a></a>S1P<sub>1</sub>/ S1P<sub>5</sub></td><td colspan=1 rowspan=1 valign=top><a name=d5420e1640 class=n-a></a>Positive results in phase II RADIANCE study<sup><a href="#ref-86">86</a></sup><br class=br>Positive results in phase III SUNBEAM study<sup><a href="#ref-87">87</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d5420e1651 class=n-a></a>Ozanimod effectively crosses the<br class=br>BBB and demonstrated a high<br class=br>volume of distribution in both<br class=br>mouse and rat species, 10 and<br class=br>13 L/kg, with a brain-to-blood ratio<br class=br>of 10:1 and 16:1, respectively<sup><a href="#ref-88">88</a></sup>.<br class=br>MPO = 3.7</td></tr><tr><a name=d5420e1672 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e1674 class=n-a></a>Ceralifimod</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1677 class=n-a></a> <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T20.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T20.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T20.gif"></a> </td><td colspan=1 rowspan=1 valign=top><a name=d5420e1682 class=n-a></a>S1P<sub>1</sub>/ S1P<sub>5</sub></td><td colspan=1 rowspan=1 valign=top><a name=d5420e1690 class=n-a></a>Positive results in phase II and phase II extension<br class=br>for RRMS (DreaMS)<sup><a href="#ref-89">89</a></sup><br class=br>Merck is not pursuing phase III development.</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1700 class=n-a></a>Capability to pass the BBB has not<br class=br>been assessed.<br class=br>MPO = 3.0</td></tr><tr><a name=d5420e1708 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e1710 class=n-a></a>Ponesimod</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1713 class=n-a></a> <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T21.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T21.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T21.gif"></a> </td><td colspan=1 rowspan=1 valign=top><a name=d5420e1718 class=n-a></a>S1P<sub>1</sub></td><td colspan=1 rowspan=1 valign=top><a name=d5420e1723 class=n-a></a>Positive results in phase II<sup><a href="#ref-90">90</a></sup><br class=br>Phase II extension is active.<br class=br>Phase III POINT study is currently recruiting.</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1733 class=n-a></a>Capability to pass the BBB has not<br class=br>been assessed.<br class=br>MPO = 1.9</td></tr><tr><a name=d5420e1741 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e1743 class=n-a></a>GSK2018682</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1746 class=n-a></a> <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T22.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T22.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T22.gif"></a> </td><td colspan=1 rowspan=1 valign=top><a name=d5420e1751 class=n-a></a>S1P<sub>1</sub>/ S1P<sub>5</sub></td><td colspan=1 rowspan=1 valign=top><a name=d5420e1759 class=n-a></a>Phase I trial completed</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1762 class=n-a></a>Capability to pass the BBB has not<br class=br>been assessed.<br class=br>MPO = 3.1</td></tr><tr><a name=d5420e1770 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e1772 class=n-a></a>Laquinimod</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1775 class=n-a></a> <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T23.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T23.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T23.gif"></a> </td><td colspan=1 rowspan=1 valign=top><a name=d5420e1780 class=n-a></a>APC/nuclear factor-kappa B (NF-κB)<br class=br>pathway<br class=br>/Inhibits cytokines and lymphocyte<br class=br>migration into the central nervous<br class=br>system</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1791 class=n-a></a>Phase III trial completed for RRMS</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1794 class=n-a></a>The laquinimod concentration in the<br class=br>cerebrum, cerebellum and spinal<br class=br>cord reached about 7% to 8% in<br class=br>relation to the blood concentration<br class=br>at the time point of maximum<br class=br>concentration (2 hours post-dose)<br class=br>in healthy rats with intact BBB<sup><a href="#ref-91">91</a></sup>.<br class=br>MPO = 5.3</td></tr><tr><a name=d5420e1818 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e1820 class=n-a></a>Teriflunomide</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1823 class=n-a></a> <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T24.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T24.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T24.gif"></a> </td><td colspan=1 rowspan=1 valign=top><a name=d5420e1828 class=n-a></a>Pyrimidine synthesis inhibitor</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1831 class=n-a></a>FDA approved in 2012 for RRMS<br class=br>Cochrane review, only 14 mg/day delays<br class=br>disability<sup><a href="#ref-92">92</a></sup><br class=br>Positive results in phase III TOWER study for<br class=br>RRMS<sup><a href="#ref-93">93</a></sup><br class=br>Active phase III study for patients with first clinical<br class=br>episode was suggestive of MS (TERICIS).</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1853 class=n-a></a>Only limited penetration across the<br class=br>BBB (brain-to-blood ratio ≤2%).<br class=br>MPO = 5.4</td></tr><tr><a name=d5420e1861 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e1863 class=n-a></a>Leflunomide</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1866 class=n-a></a> <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T25.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T25.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T25.gif"></a> </td><td colspan=1 rowspan=1 valign=top><a name=d5420e1871 class=n-a></a>Pyrimidine synthesis inhibitor</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1874 class=n-a></a>No trials reported</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1877 class=n-a></a>MPO = 5.7<br class=br>Metabolised to teriflunomide as<br class=br>detailed above</td></tr><tr><a name=d5420e1885 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e1887 class=n-a></a>Mitoxantrone</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1890 class=n-a></a> <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T26.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T26.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T26.gif"></a> </td><td colspan=1 rowspan=1 valign=top><a name=d5420e1895 class=n-a></a>Topoisomerase II inhibitor/Induces<br class=br>B-cell death</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1900 class=n-a></a>FDA approved in 2000 for SPMS, progressive-<br class=br>relapsing MS (PRMS) and worsening RRMS but<br class=br>not primary progressive MS (PPMS)</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1907 class=n-a></a>Does not cross the BBB but may<br class=br>penetrate brain tumours<sup><a href="#ref-94">94</a></sup><br class=br>MPO = 3.3</td></tr><tr><a name=d5420e1918 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e1920 class=n-a></a>Tofacitinib</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1923 class=n-a></a> <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T27.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T27.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T27.gif"></a> </td><td colspan=1 rowspan=1 valign=top><a name=d5420e1928 class=n-a></a>Inhibitor of the enzyme Janus kinase 1<br class=br>(JAK1) and Janus kinase 3 (JAK 3)</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1933 class=n-a></a>No development reported</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1936 class=n-a></a>Shows limited distribution across<br class=br>the BBB with a cerebral-to-systemic<br class=br>blood ratio of 0.05, as assessed by<br class=br>either peak plasma concentration<br class=br>(C<sub>max</sub>) or area under the curve<sup><a href="#ref-95">95</a></sup>.<br class=br>MPO = 4.8</td></tr><tr><a name=d5420e1958 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d5420e1960 class=n-a></a>Mycophenolic acid</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1963 class=n-a></a> <a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T28.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_T28.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_T28.gif"></a> </td><td colspan=1 rowspan=1 valign=top><a name=d5420e1968 class=n-a></a>IMPDH2</td><td colspan=1 rowspan=1 valign=top><a name=d5420e1971 class=n-a></a>Clinical trial completed<sup><a href="#ref-61">61</a></sup></td><td colspan=1 rowspan=1 valign=top><a name=d5420e1977 class=n-a></a>Capability to pass the BBB has not<br class=br>been assessed.<br class=br>MPO = 5.3</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d5420e1989 class=n-a></a><p id=TFN1> <sup>a</sup>MPO is assessed using the published method.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5420e2002>Adenosine deaminase: clues to the mode of action of cladribine (Mavenclad)</h2><p class="" id=d5420e2005>Adenosine deaminase is often highlighted in discussions on the mechanism of action of cladribine as the active metabolite of the drug is unable to be broken down by this enzyme<sup><a href="#ref-49">49</a></sup>. Children with adenosine deaminase deficiency have severe combined immunodeficiency disease characterised by reduced B and T lymphocyte counts<sup><a href="#ref-50">50</a></sup>. The lack of adenosine deaminase leads to an increase in dNTP levels (<a href="#f2">Figure 2</a>), which can lead to cytotoxicity by a number of different mechanisms. dNTPs are selectively toxic towards T and B cells<sup><a href="#ref-51">51</a></sup> and this susceptibility has been rationalised by examining the levels of the enzymes involved in maintaining NTP levels. Lymphocytes contain low levels of the NTP catabolic enzyme 5′-nucleotidase which favours high NTP levels in the absence of adenosine deaminase<sup><a href="#ref-52">52</a></sup>.</p><a name=f2 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_figure2.gif"><img alt="2884e857-2118-48df-8660-ad4a85477148_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/18029/2884e857-2118-48df-8660-ad4a85477148_figure2.gif"></a><div class=caption><h3>Figure 2. Mechanism of action of cladribine.</h3><p id=d5420e2037>Cladribine is taken up into cells by nucleoside transporters and then is phosphorylated to the mono-phosphate (the rate-limiting step) by deoxycytidine kinase, highly expressed in lymphocytes. Subsequent phosphorylation steps produce the active species, the triphosphate. The triphosphate cannot be efficiently degraded by adenosine deaminase, and 5′-nucleotidase has low expression in lymphocytes. This leads to high levels of the cladribine triphosphate, which is toxic to cells by a number of mechanisms, including incorporation into DNA leading to single-stranded breaks.</p></div></div><p class="" id=d5420e2044>In the case of cladribine action, the drug enters the cell via nucleoside transporters and is successively phosphorylated to the triphosphate (<a href="#f2">Figure 2</a>). The rate-limiting step for this process is the initial phosphorylation by cytidine kinase, an enzyme that is highly expressed in lymphocytes (<a href="#f2">Figure 2</a>)<sup><a href="#ref-53">53</a></sup>. Owing to the inability of cladribine triphosphate to be broken down by adenosine deaminase and the low levels of 5′ nucleotidase in lymphocytes, this active metabolite incorporates into DNA, leading to single-stranded DNA breaks and ribonucleotide reductase inhibition. This is thought to be the major cause of lymphocyte toxicity. Other mechanisms include disruption of DNA repair and an epigenetic effect.</p><p class="" id=d5420e2057>Cladribine has medium oral absorption (37%–51% bioavailable) with a half-life of 5.7 to 19.7 hours<sup><a href="#ref-54">54</a></sup>. The drug achieves very good levels in cerebrospinal fluid (25% of plasma levels) and is metabolised mostly in the blood (in contrast to most drugs)<sup><a href="#ref-55">55</a></sup>. The testing and registration of cladribine for MS have a long and tortuous history<sup><a href="#ref-56">56</a></sup> culminating in the CLARITY (Cladribine Tablets Treating Multiple Sclerosis Orally) phase 3<sup><a href="#ref-57">57</a></sup> and CLARITY extension<sup><a href="#ref-2">2</a></sup> study. The drug is efficacious in reducing relapses following short courses of treatment (4–5 days) at 3.5 or 5.25 mg/kg with reductions in relapse rate of 57.6% and 54.5% versus placebo, respectively. Side effects such as lymphopenia and infection were predictable in line with an agent that depletes B and T cells. Cladribine is licensed for hairy cell leukaemia and B-cell chronic lymphocytic leukaemia. In 2017, it was approved for MS in Europe<sup><a href="#ref-58">58</a></sup> and is marketed by Merck KGaA (EMD Serono in the US) as Mavenclad. Merck filed for FDA approval on 30 July 2018.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5420e2088>Inosine-5′-monophosphate dehydrogenases (IMPDH1 and IMPDH2)</h2><p class="" id=d5420e2091>IMPDH1 and IMPDH2 catalyse the conversion of inosine 5-phosphate to xanthosine 5-phosphate. IMPDH2 is the rate-limiting enzyme for guanosine biosynthesis<sup><a href="#ref-59">59</a></sup>, and there are similarities with the mechanism of cladribine above. Inhibitors of these enzymes are generally immune-suppressive. Mycophenolate mofetil is an old drug which has recently shown some clinical benefit in MS<sup><a href="#ref-60">60</a>,<a href="#ref-61">61</a></sup>. It is a non-selective inhibitor of IMPDH1 and 2 and has Ki values of 40 and 10 nM, respectively<sup><a href="#ref-62">62</a></sup>. The mechanism of immune suppression has been characterised in systemic lupus erythematosus<sup><a href="#ref-63">63</a></sup> as slowing B-cell proliferation and plasmablast formation. The lack of selectivity for mycophenolate and other older drugs has led to a search for more selective inhibitors. Sanglifehrin is a natural product with immune-suppressive properties that only recently have been characterised as working through inhibition of IMPDH2<sup><a href="#ref-64">64</a></sup>. The spiroketal moiety of sanglifehrin is responsible for this activity, forming a ternary complex between IMPDH2, sanglifehrin, and cyclophilin A. Sappanone is a covalent and selective inhibitor of IMPDH2 over IMPDH1, binding to the Cys140 on the protein<sup><a href="#ref-65">65</a></sup>, and this type of compound may offer promise for an effective treatment with fewer side effects.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5420e2126>Dihydroorotate dehydrogenase inhibitors: teriflunomide</h2><p class="" id=d5420e2129>Dihydroorotate dehydrogenase (DHODH) is a critical mitochondrial enzyme involved in the <i>de novo</i> biosynthesis of pyrimidines. Inhibiting this enzyme limits the available pyrimidine reserve needed for the increased proliferation of T and B lymphocytes seen in patients with MS<sup><a href="#ref-66">66</a>,<a href="#ref-67">67</a></sup>. This lowers the inflammatory response to auto-antigens by decreasing the number of activated T and B cells available to cross the blood–brain barrier into the CNS.</p><p class="" id=d5420e2142>Teriflunomide acts primarily as a non-competitive and selective inhibitor of DHODH and is approved for the treatment of relapsing forms of MS (RRMS). The registration and approval of teriflunomide were due to the success of three randomised placebo-controlled trials in relapsing MS, which demonstrated that daily oral dosing of 7 to 14 mg is effective versus placebo in three key measures: relapses, disability progression and brain lesions. Clinical trial III (Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis, or TOPIC) showed that 72% of patients remained relapse-free on teriflunomide 14 mg versus 62% with placebo<sup><a href="#ref-96">96</a></sup>. A recent study on the effect of teriflunomide on different immune cell subpopulations in patients with MS indicated that, while teriflunomide significantly reduces absolute counts of total CD19<sup>+</sup> B cells and mature and regulatory B-cell subsets, it affects T-cell numbers to a noticeably lesser extent and shows no detectable effect on natural killer (NK) cell numbers<sup><a href="#ref-97">97</a></sup>. However, the reduction in memory B cells is modest, and a more recent study suggests that when teriflunomide is used as a second-line treatment, relapse rates of patients with RRMS were increased compared with those who switched to dimethyl fumarate<sup><a href="#ref-98">98</a></sup>. Oral bioavailability of teriflunomide is about 100%, and peak plasma levels are achieved within 1–2 hours of ingestion<sup><a href="#ref-99">99</a></sup>. Teriflunomide is the active metabolite of leflunomide (<a href="#T2">Table 2</a>)<sup><a href="#ref-100">100</a>,<a href="#ref-101">101</a></sup>. Further data on teriflunomide were presented at the 2018 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting to indicate a reduction in T-cell receptor (TCR) repertoire diversity in patients with RRMS. Metabolic analysis of T cells of patients showed increased metabolic potential over controls; the authors consider that teriflunomide can improve energy production in T cells via dihydroorotate inhibition<sup><a href="#ref-102">102</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5420e2182>Epstein–Barr virus as a target</h2><p class="" id=d5420e2185>Should EBV be established as the trigger for MS or as a contributor to the pathology, then specific EBV anti-virals might also offer a route to treatment. A small study using autologous EBV-specific T-cell therapy has been reported<sup><a href="#ref-103">103</a></sup> noting promising clinical improvement. Unfortunately, however, the state of EBV anti-viral chemotherapy is poor<sup><a href="#ref-104">104</a></sup>.</p><p class="" id=d5420e2196>Maribavir, a nucleoside anti-viral, has been investigated in detail for inhibition of EBV replication<sup><a href="#ref-105">105</a></sup>. This drug initially stalled in development for cytomegalovirus (CMV) but achieved success in the treatment of haemopoietic stem cell transplant and solid organ transplant patients<sup><a href="#ref-106">106</a></sup>. It has recently been granted breakthrough status by the FDA. It is, however, not currently being developed for EBV<sup><a href="#ref-107">107</a></sup>. Maribavir works through the EBV protein kinase BGLF4<sup><a href="#ref-105">105</a></sup> rather than through a standard nucleoside target. Phosphonate anti-viral nucleosides, including HPMP-5-azaC, have shown EBV efficacy <i>in vitro</i> and in animal models<sup><a href="#ref-108">108</a></sup>. Herpes viruses may incorporate their own viral thymidine kinase and this is responsible for the high selectivity and low toxicity of agents such as acyclovir. Although viral EBV thymidine kinase has restricted specificity compared with other herpes virus thymidine kinases<sup><a href="#ref-109">109</a></sup>, some nucleosides such as KAY-2-41 and KAY-39-149 show high activity against EBV<sup><a href="#ref-110">110</a></sup>. No development of these agents is reported. The similarity between the mode of action of cladribine and that of anti-viral nucleosides is obvious, but there is currently no report of the activity (if any) of cladribine against EBV-infected cells. The development of EBV vaccines is problematic<sup><a href="#ref-111">111</a></sup>, but efforts are continuing and some recent success was observed in animals<sup><a href="#ref-112">112</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5420e2242>Proteasome inhibitors bortezomib and carfilzomib</h2><p class="" id=d5420e2245>Bortezomib is a proteasome inhibitor used for the treatment of multiple myeloma and mantle cell lymphoma, two B cell–associated cancers. Bortezomib preferentially affects plasma cell differentiation and survival through its action on the nuclear factor-kappa B (NF-κB) pathway. This pathway is also key in inflammatory and autoimmune diseases<sup><a href="#ref-113">113</a></sup>. The proteasome is also directly involved with processing of MHC class I peptides<sup><a href="#ref-114">114</a></sup>. Following B-cell activation, B cells become more susceptible to proteasome inhibition<sup><a href="#ref-115">115</a></sup>. Thus, bortezomib has some selectivity in inducing apoptosis in activated B cells (plasma cells). Bortezomib has been trialled in the autoimmune diseases refractory systemic lupus erythematosus and neuromyelitis optica spectrum disorder<sup><a href="#ref-116">116</a></sup> and demonstrated some efficacy<sup><a href="#ref-117">117</a></sup>. A negative aspect of bortezomib is the reported chemotherapy-induced peripheral neuropathy. This is caused by dysregulation of sphingosine-1-phosphate receptor-1 in astrocytes, which can be treated with fingolimod<sup><a href="#ref-118">118</a></sup>. Carfilzomib is a recently approved proteasome inhibitor for lymphomas. A recent study showed that carfilzomib together with other proteasome inhibitors had an effect on activated B cells and on naïve and—importantly from an MS perspective—memory B cells<sup><a href="#ref-119">119</a></sup>. There appears to be potential for the use of proteasome inhibitors in MS, particularly if their action on different subtypes of B cells becomes better understood and if the side effects are minimised.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5420e2280>Bruton’s (B-cell) tyrosine kinase inhibitors</h2><p class="" id=d5420e2283>Bruton’s (B-cell) tyrosine kinase (BTK) is an essential kinase for the maturation of B cells together with phosphatidylinositol 3-kinase isoform p110delta (PI3Kδ). This pathway is important for autoimmune diseases and B-cell malignancies. In MS, BTK inhibitors show potential for highly specific removal of B cells and potential to diminish autoantibody release in rheumatoid arthritis models<sup><a href="#ref-120">120</a></sup>. The first covalent BTK inhibitor to be marketed was ibrutinib, a covalent tyrosine kinase inhibitor with activity against BTK and now licensed for the B-cell malignancies mantle cell lymphoma, del17p chronic lymphocytic leukaemia<sup><a href="#ref-121">121</a></sup>, and Waldenström’s macroglobulinemia<sup><a href="#ref-122">122</a></sup>. Although no development of ibrutinib for MS has been reported, two other inhibitors have reached development: evobrutinib (Merck KGgA) has reported positive phase IIB data, and PRN2246 (Principia/Sanofi) is still at an earlier stage<sup><a href="#ref-123">123</a></sup>. Quite recently, at the 2018 Congress of the ECTRIMS, Merck presented clinical data using evobrutinib in patients with RRMS and illustrated positive results by reduction of T1<sup>+</sup>Gd lesions compared with placebo, justifying future clinical studies<sup><a href="#ref-124">124</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5420e2313>PI3Kδ inhibitors</h2><p class="" id=d5420e2316>As indicated above, PI3Kδ inhibitors can prevent the maturation of B cells and therefore are candidates for MS therapy. In contrast to BTK, this protein is also expressed in T cells. The expression of this enzyme is not restricted to B cells and thus could exhibit off-target effects. The gene <i>PIK3R1</i>—phosphatidylinositol 3-kinase regulatory subunit alpha (PI3-kinase regulatory subunit alpha)—has been listed as a priority gene from an interaction map analysis of GWAS data<sup><a href="#ref-23">23</a></sup>. PIK3R1 is linked to a primary immunodeficiency resulting in low or absent circulating B cells<sup><a href="#ref-125">125</a></sup>. So far, there have been no reports of development of idelalisib or other PI3Kδ inhibitors for MS. A black box warning has been issued for idelalisib which may hamper its use<sup><a href="#ref-126">126</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5420e2337>B cell–activating factor and tumour necrosis factor alpha regulators</h2><p class="" id=d5420e2340>B cell–activating factor (BAFF) is a member of the tumour necrosis factor (TNF) family of receptors<sup><a href="#ref-127">127</a></sup> and is a key survival factor for B-cell subsets encoded by the <i>TNFSF13B</i> gene. A secreted cytokine, it is a ligand for three TNF receptors: TACI, BCMS and BAFF-R. The interaction between BAFF and BAFF-R activates the canonical NF-κB signalling pathway for B-cell survival and activation. The association of BAFF with MS has been known since the early 2000s; BAFF is upregulated in astrocytes within MS lesions<sup><a href="#ref-128">128</a></sup>. A recent study demonstrated an association of a variant of <i>TNFSF13B</i> (BAFF-var) with MS<sup><a href="#ref-129">129</a></sup>. The same study showed no involvement of BAFF-var with multiple T-cell traits, consistent with an effect on B cells and particularly on memory B cells. Biological therapies that target this cytokine are available. This gene appears to be a rare example of one that is associated with the disease by genetics and has also been drugged. The actions of this cytokine and others on B cells and on the course of the disease have not been fully elucidated. Atacicept—a fusion protein of BAFF and a proliferation-inducing ligand (APRIL)—worsens MS, an effect ascribed to an increase in memory B cells<sup><a href="#ref-7">7</a></sup>.</p><p class="" id=d5420e2366>CP-25 is a derivative of the natural product paeoniflorin<sup><a href="#ref-130">130</a></sup>, which is able to inhibit B-cell proliferation in a similar manner to rituximab (CD20 B-cell targeting antibody) and etanercept (TNF receptor chimera) and also downregulate the expression of BAFF-R on B cells. The mechanism of these effects is not reported<sup><a href="#ref-131">131</a></sup>. It will be interesting to note the progression of this compound and ones with a similar mode of action. The effect of CP-25 on B-cell subsets was more modest than that of rituximab<sup><a href="#ref-131">131</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5420e2385>Dimethylfumarate: Tecfidera</h2><p class="" id=d5420e2388>Dimethylfumarate (DMF) is an old drug originally used to treat psoriasis. Rapid metabolism converts DMF to monomethylfumarate, the main species in circulation. This compound can react with glutathione to trigger an anti-oxidant response. The main mechanism of action is thought to be via activation of the transcription factor Nrf2, thus inducing a protective effect on cells<sup><a href="#ref-45">45</a></sup>, although different targets of DMF have been observed<sup><a href="#ref-132">132</a></sup>. Multiple actions on the immune system in pwMS have been noted<sup><a href="#ref-133">133</a></sup>, including a potentially important decrease in CD19<sup>+</sup>CD27<sup>+</sup> memory B cells<sup><a href="#ref-134">134</a></sup>. This may in fact be a main mechanism of action due to the dramatic effects observed with other B cell–targeted therapies.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5420e2417>Janus kinase inhibitors</h2><p class="" id=d5420e2420>Janus kinases (JAKs) are downstream effectors of cytokine receptors and thus are potentially useful in MS given the importance of cytokines in driving MS. Although JAK inhibitors, such as tofacitinib, are in trials for many autoimmune diseases, MS is not currently a disease indication for inhibitors of this type<sup><a href="#ref-135">135</a></sup>. The <i>JAK2</i> gene is listed as a priority gene from the protein interaction analysis in the recent GWAS<sup><a href="#ref-23">23</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5420e2437>Sphingosine-1-phosphate receptor inhibitors</h2><p class="" id=d5420e2440>Fingolimod is a prodrug that is activated by phosphorylation with sphingosine kinases. The phosphate form can then bind and initially activate receptors sphingosine-1-phosphate 1 (S1P1), S1P3, S1P4 and S1P5<sup><a href="#ref-136">136</a></sup>. The action on the S1P1 receptor is thought to mediate as a functional antagonism with removal of the receptor from the membrane and proteasomal degradation. The S1P1 receptor is essential for lymphocyte trafficking from lymph nodes. Although the mechanism was thought to be primarily through T cells, studies also point to an effect on astrocytes and microglia<sup><a href="#ref-137">137</a></sup> and this may be via the S1P3 receptor<sup><a href="#ref-138">138</a></sup>. Despite increasing serum levels of BAFF in pwMS, fingolimod did not activate memory B cells or plasma cells<sup><a href="#ref-139">139</a></sup>. The overall beneficial effects of fingolimod in MS are tempered by side effects<sup><a href="#ref-140">140</a></sup> and have stimulated the development of more selective drugs such as siponimod ponesimod and ozanimod<sup><a href="#ref-136">136</a></sup>. Only detailed clinical analysis will establish the relative effectiveness of these compounds, particularly as they must now compete with the emerging B cell–directed therapies.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5420e2471>Aryl hydrocarbon receptor</h2><p class="" id=d5420e2474>Laquinimod, a quinolone-3-carboxamide derivative, is an innovative oral anti-inflammatory drug developed for the treatment of RRMS, PPMS and Huntington’s disease. Preclinical studies have shown that laquinimod reduces inflammatory cell infiltrates in the CNS. Furthermore, laquinimod suppresses clinical signs in EAE models and decreases the formation of meningeal B-cell aggregates in EAE mice<sup><a href="#ref-141">141</a>–<a href="#ref-143">143</a></sup>. Three phase 3 studies evaluating the efficacy and safety of laquinimod 0.6 mg as a treatment for RRMS have been conducted. The first study (ALLEGRO, or Assessment of Oral Laquinimod in Preventing Progression in Multiple Sclerosis) showed statistically significant differences between laquinimod and placebo in reducing the risk of sustained disability progression and rate of MRI-measured brain volume loss<sup><a href="#ref-144">144</a></sup>. The second study (BRAVO) did not reach the primary endpoint of the trial but indicated a significant reduction in disability progression and brain atrophy<sup><a href="#ref-145">145</a></sup>. CONCERTO (The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis) was the third study to be completed, and it failed to meet its primary endpoint of a difference between patients receiving laquinimod 0.6 mg/day and those receiving equivalent placebo in confirmed 3-month disease progression; however, it did demonstrate a significant effect on reducing brain volume loss and clinical relapses<sup><a href="#ref-146">146</a></sup>.</p><p class="" id=d5420e2496>The therapeutic effect of laquinimod was recently found to be dependent on aryl hydrocarbon receptor (AhR) activation and has been shown to induce several genes downstream linked with the AhR pathway. Among these genes were <i>CYP1A1</i> and <i>AHRR</i>, showing the highest average fold change in both naïve and EAE mice<sup><a href="#ref-147">147</a></sup>. AhR activation via laquinimod alters the phenotype of antigen-presenting cells and autoreactive T and B cells, reducing the humoral response associated with MS<sup><a href="#ref-143">143</a>,<a href="#ref-148">148</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5420e2519>Topoisomerase II inhibitors: mitoxantrone</h2><p class="" id=d5420e2522>Topoisomerase II is a nuclear enzyme that modifies the topology of DNA by catalysing the transient breaking and rejoining of the phosphodiester backbone<sup><a href="#ref-149">149</a></sup>. Topoisomerase II inhibitors block the action of these DNA enzymes, interrupting their catalytic cycle, and are thought to give rise to the presence of protein-associated double-strand breaks, which may be lethal to a cell<sup><a href="#ref-150">150</a>,<a href="#ref-151">151</a></sup>. Two forms of topoisomerase II exist, possibly products of a gene duplication event, topoisomerase II α and β. Mitoxantrone, a synthetic antineoplastic anthracenedione, was shown to target both topoisomerase II α and β and consequently interfere with DNA repair<sup><a href="#ref-152">152</a></sup>. By inhibiting DNA replication and DNA-dependent RNA synthesis, mitoxantrone makes the cell incapable of dividing, thus suppressing the proliferation of autoreactive T cells, B cells, macrophages and other antigen-presenting cells that mediate myelin degradation<sup><a href="#ref-153">153</a></sup>. Mitoxantrone was initially proven to be effective in EAE<sup><a href="#ref-154">154</a></sup>. In addition, it has proven efficacy in the treatment of worsening RRMS, SPMS and PRMS as assessed in three controlled clinical trials<sup><a href="#ref-155">155</a>–<a href="#ref-157">157</a></sup>. However, the risks of severe adverse events of mitoxantrone are similar to those seen with other anthracyclines—myelosuppression and cardiotoxicity—and it has seen decreased use because of the introduction of newer therapies such as fingolimod<sup><a href="#ref-158">158</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5420e2563>Glatiramer acetate</h2><p class="" id=d5420e2566>Glatiramer acetate (Copaxone) is a simple but random polymer of the amino acids Ala, Glu, Lys and Tyr<sup><a href="#ref-159">159</a></sup>. Originally conceived to mimic basic myelin, the drug is an immunomodulator and shows activity in the EAE animal model. A Cochrane review concluded that it had no effect on disease progression but showed some efficacy in “relapse related clinical outcomes”<sup><a href="#ref-160">160</a></sup>. In common with effects of other agents, its effects were thought to be T cell–related, but recent studies have pointed to a correlation with B-cell activity<sup><a href="#ref-161">161</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5420e2585>Discussion</h2><p class="" id=d5420e2588>The study of the genetics associated with MS continues to improve our understanding of its mechanism, further implicating B cells and EBV in MS pathogenesis. However, an indication of the limitation of the genetic approach and the importance of other factors is that genetic susceptibility has thus far not proven useful in diagnosis. Even individuals with a high genetic susceptibility are unlikely to develop the disease<sup><a href="#ref-4">4</a></sup>. The ideal scenario for genetic studies is that a key target that triggers the disease or is crucial in the pathology will emerge. This idea is, of course, best illustrated by the anti-cancer drug Gleevec, which targets the bcr-abl kinase. However, even with monogenic diseases, such as Huntington’s, therapies can be slow to appear<sup><a href="#ref-162">162</a></sup>. For Alzheimer’s disease, there have been several discoveries linking particular genes and proteins to the disease but this has not produced any therapies to date. Complex multifactorial diseases such as MS would seem to be unlikely candidates for a magic bullet resulting from genetic studies.</p><p class="" id=d5420e2599>The effectiveness of the new B cell–targeted agents, such as the CD20 antibodies and cladribine, has placed B-cell therapies at the centre of MS therapy. These therapies, however, have a non-optimal therapeutic index, and investigation of alternative B-cell agents is warranted. With cheap and effective small molecules such as cladribine already available, new agents need to demonstrate significantly improved side-effect profiles. This review concentrated on the promise of new small-molecule agents as B cell–directed drugs. Clearly, agents such as the BTK inhibitor evobrutinib have already shown some potential in clinical trials<sup><a href="#ref-123">123</a></sup>.</p><p class="" id=d5420e2606>Accumulating evidence places EBV as central to the disease, but no effective control of EBV has been achieved as yet. The only advanced therapy likely to have EBV efficacy, maribavir, has not been trialled for EBV. Maribavir is effective in human CMV therapy, and a trial in MS would be justified. Maribavir shows good CNS penetration, allowing it to access CNS cells such as astrocytes that are known to be infected with EBV. If EBV is responsible only for activation of the immune system, then EBV-specific treatment will have an effect similar to that of current immune therapies; however, if significant EBV infection affects other cells such as astrocytes, then a more pronounced effect should be evident. While debate continues on the role of EBV in MS, it will be difficult to address this question without an effective EBV therapy. B-cell therapies remove only the latent form and do not eliminate the virus elsewhere in the body. The marmoset model is perhaps superior to rodent models as a way to evaluate MS therapies; testing anti-EBV therapies would require that the CalHV3 virus show a sensitivity similar to that of EBV to the anti-viral agent.</p><p class="" id=d5420e2609>Treatment options for patients with MS have improved enormously over the last few decades; however, current therapies are expensive and ultimately do not prevent disease progression. Small molecules represent a more affordable and sustainable class of drugs that are favourable for MS in particular because of higher blood–brain barrier penetration. Here, we have discussed small molecules that target B cells, and EBV-infected B cells, and are currently being pursued or warrant future investigation in the context of MS. However, few of the genes and pathways targeted affect MS susceptibility genes that are implicated in the mechanism of the disease. The noteworthy progress of anti-CD20 antibodies and cladribine has brought the role of B cells in MS pathology to the forefront of current research. This opens the door to numerous exciting possibilities to develop unique, affordable and easily maintainable therapies.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d5420e2615>Methodology</h2><p class="" id=d5420e2618>Gene and protein data were downloaded from UniprotKB, a curated high-quality database. Gene lists were inputted to <a target=xrefwindow href="https://www.uniprot.org/uploadlists/" id=d5420e2620>https://www.uniprot.org/uploadlists/</a>, and the data were downloaded in tab format and saved in Excel (<a href="#ST1">Supplementary Table</a>). Selected gene data were supplemented with PubMed searches. Gene lists were taken from the following sources: Patsopoulos 2017<sup><a href="#ref-23">23</a></sup>, Beecham 2013<sup><a href="#ref-24">24</a></sup> (both IMSGC), Fischer<sup><a href="#ref-43">43</a></sup>, Sevastou<sup><a href="#ref-163">163</a></sup> (RNA-Seq mouse EAE) and EBV genes Afrasiabi 2018<sup><a href="#ref-25">25</a></sup>.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d5420e1 class=n-a></a><h2 class=main-title id=d5897>Grant information</h2><p>AG was funded by a grant from the National MS Society – Fast Forward group (FF-1602-07939). KT was funded by a PhRMA Foundation Predoctoral fellowship in Pharmacology.</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </p></div><div class=back-section><a name=d5420e2652 class=n-a></a><h2 class=main-title id=d5420e2654>Supplementary material</h2><p class="" id=ST1>Supplementary Table 1 - Gene lists</p><p class="" id=d5420e2660><a target=xrefwindow href="https://f1000researchdata.s3.amazonaws.com/supplementary/16495/9b22a6cf-2cef-4b78-9237-c835f6bb6379_Supplementary_Table_1_revised_V2.xlsx" id=d5420e2661>Click here to access the data</a></p></div><div class=back-section><a name=d5420e2665 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d6420>References</h2><div class="section ref-list"><a name=d5420e2665 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d5420e2672 class=n-a></a>Jacques FH: Defining the clinical course of multiple sclerosis: the 2013 revisions. <i>Neurology.</i> 2015; <b>84</b>: 963. <a target=xrefwindow id=d5420e2680 href="https://doi.org/10.1016/S1474-4422(17)30470-2">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732364658"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e2689 class=n-a></a>Thompson AJ, Banwell BL, Barkhof F, <i> et al.</i>: Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurol.</i> 2018; <b>17</b>(2): 162–173. <a target=xrefwindow id=d5420e2700 href="http://www.ncbi.nlm.nih.gov/pubmed/29275977">PubMed Abstract </a> | <a target=xrefwindow id=d5420e2703 href="https://doi.org/10.1016/S1474-4422(17)30470-2">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732364658">F1000 Recommendation</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d5420e2721 class=n-a></a>Booth DR, Ding N, Parnell GP, <i> et al.</i>: Cistromic and genetic evidence that the vitamin D receptor mediates susceptibility to latitude-dependent autoimmune diseases. <i>Genes Immun.</i> 2016; <b>17</b>(4): 213–219. <a target=xrefwindow id=d5420e2732 href="http://www.ncbi.nlm.nih.gov/pubmed/26986782">PubMed Abstract </a> | <a target=xrefwindow id=d5420e2735 href="https://doi.org/10.1038/gene.2016.12">Publisher Full Text </a> | <a target=xrefwindow id=d5420e2739 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4895389">Free Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d5420e2748 class=n-a></a>Parnell GP, Booth DR: The Multiple Sclerosis (MS) Genetic Risk Factors Indicate both Acquired and Innate Immune Cell Subsets Contribute to MS Pathogenesis and Identify Novel Therapeutic Opportunities. <i>Front Immunol.</i> 2017; <b>8</b>: 425. <a target=xrefwindow id=d5420e2756 href="http://www.ncbi.nlm.nih.gov/pubmed/28458668">PubMed Abstract </a> | <a target=xrefwindow id=d5420e2759 href="https://doi.org/10.3389/fimmu.2017.00425">Publisher Full Text </a> | <a target=xrefwindow id=d5420e2762 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5394466">Free Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d5420e2771 class=n-a></a>Hilven K, Patsopoulos NA, Dubois B, <i> et al.</i>: Burden of risk variants correlates with phenotype of multiple sclerosis. <i>Mult Scler.</i> 2015; <b>21</b>(13): 1670–1680. <a target=xrefwindow id=d5420e2782 href="http://www.ncbi.nlm.nih.gov/pubmed/25948629">PubMed Abstract </a> | <a target=xrefwindow id=d5420e2785 href="https://doi.org/10.1177/1352458514568174">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731387389"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e2795 class=n-a></a>Lehmann-Horn K, Kinzel S, Weber MS: Deciphering the Role of B Cells in Multiple Sclerosis-Towards Specific Targeting of Pathogenic Function. <i>Int J Mol Sci.</i> 2017; <b>18</b>(10): pii: E2048. <a target=xrefwindow id=d5420e2803 href="http://www.ncbi.nlm.nih.gov/pubmed/28946620">PubMed Abstract </a> | <a target=xrefwindow id=d5420e2806 href="https://doi.org/10.3390/ijms18102048">Publisher Full Text </a> | <a target=xrefwindow id=d5420e2809 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5666730">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731387389">F1000 Recommendation</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727275259"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e2827 class=n-a></a>Baker D, Marta M, Pryce G, <i> et al.</i>: Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. <i>EBioMedicine.</i> 2017; <b>16</b>: 41–50. <a target=xrefwindow id=d5420e2838 href="http://www.ncbi.nlm.nih.gov/pubmed/28161400">PubMed Abstract </a> | <a target=xrefwindow id=d5420e2841 href="https://doi.org/10.1016/j.ebiom.2017.01.042">Publisher Full Text </a> | <a target=xrefwindow id=d5420e2845 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5474520">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727275259">F1000 Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732846666"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e2863 class=n-a></a>Rahmanzadeh R, Weber MS, Brück W, <i> et al.</i>: B cells in multiple sclerosis therapy-A comprehensive review. <i>Acta Neurol Scand.</i> 2018; <b>137</b>(6): 544–556. <a target=xrefwindow id=d5420e2874 href="http://www.ncbi.nlm.nih.gov/pubmed/29512131">PubMed Abstract </a> | <a target=xrefwindow id=d5420e2877 href="https://doi.org/10.1111/ane.12915">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732846666">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d5420e2895 class=n-a></a>Bose T: Role of Immunological Memory Cells as a Therapeutic Target in Multiple Sclerosis. <i>Brain Sci.</i> 2017; <b>7</b>(11): pii: E148 <a target=xrefwindow id=d5420e2903 href="http://www.ncbi.nlm.nih.gov/pubmed/29112130">PubMed Abstract </a> | <a target=xrefwindow id=d5420e2906 href="https://doi.org/10.3390/brainsci7110148">Publisher Full Text </a> | <a target=xrefwindow id=d5420e2909 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5704155">Free Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d5420e2918 class=n-a></a>Sefia E, Pryce G, Meier UC, <i> et al.</i>: Depletion of CD20 B cells fails to inhibit relapsing mouse experimental autoimmune encephalomyelitis. <i>Mult Scler Relat Disord.</i> 2017; <b>14</b>: 46–50. <a target=xrefwindow id=d5420e2929 href="http://www.ncbi.nlm.nih.gov/pubmed/28619431">PubMed Abstract </a> | <a target=xrefwindow id=d5420e2932 href="https://doi.org/10.1016/j.msard.2017.03.013">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732675804"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e2941 class=n-a></a>Bjelobaba I, Begovic-Kupresanin V, Pekovic S, <i> et al.</i>: Animal models of multiple sclerosis: Focus on experimental autoimmune encephalomyelitis. <i>J Neurosci Res.</i> 2018; <b>96</b>(6): 1021–1042. <a target=xrefwindow id=d5420e2952 href="http://www.ncbi.nlm.nih.gov/pubmed/29446144">PubMed Abstract </a> | <a target=xrefwindow id=d5420e2955 href="https://doi.org/10.1002/jnr.24224">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732675804">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d5420e2974 class=n-a></a>Lassmann H, Niedobitek G, Aloisi F, <i> et al.</i>: Epstein-Barr virus in the multiple sclerosis brain: a controversial issue--report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. <i>Brain.</i> 2011; <b>134</b>(Pt 9): 2772–2786. <a target=xrefwindow id=d5420e2985 href="http://www.ncbi.nlm.nih.gov/pubmed/21846731">PubMed Abstract </a> | <a target=xrefwindow id=d5420e2988 href="https://doi.org/10.1093/brain/awr197">Publisher Full Text </a> | <a target=xrefwindow id=d5420e2992 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3170536">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d5420e3001 class=n-a></a>Pakpoor J, Ramagopalan SV: Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: yes. <i>Mult Scler J.</i> 2013; <b>19</b>(13): 1690–1691. <a target=xrefwindow id=d5420e3009 href="http://www.ncbi.nlm.nih.gov/pubmed/24218486">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3012 href="https://doi.org/10.1177/1352458513506505">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732595781"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e3021 class=n-a></a>Hassani A, Corboy JR, Al-Salami S, <i> et al.</i>: Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells. <i>PLoS One.</i> 2018; <b>13</b>(2): e0192109. <a target=xrefwindow id=d5420e3032 href="http://www.ncbi.nlm.nih.gov/pubmed/29394264">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3035 href="https://doi.org/10.1371/journal.pone.0192109">Publisher Full Text </a> | <a target=xrefwindow id=d5420e3039 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5796799">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732595781">F1000 Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735120627"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e3057 class=n-a></a>Pender MP: Preventing and curing multiple sclerosis by controlling Epstein-Barr virus infection. <i>Autoimmun Rev.</i> 2009; <b>8</b>(7): 563–568. <a target=xrefwindow id=d5420e3065 href="http://www.ncbi.nlm.nih.gov/pubmed/19254880">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3068 href="https://doi.org/10.1016/j.autrev.2009.01.017">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735120627">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d5420e3086 class=n-a></a>Mentis AA, Dardiotis E, Grigoriadis N, <i> et al.</i>: Viruses and endogenous retroviruses in multiple sclerosis: From correlation to causation. <i>Acta Neurol Scand.</i> 2017; <b>136</b>(6): 606–616. <a target=xrefwindow id=d5420e3097 href="http://www.ncbi.nlm.nih.gov/pubmed/28542724">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3100 href="https://doi.org/10.1111/ane.12775">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735120668"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e3109 class=n-a></a>Kearns PKA, Casey HA, Leach JP: Hypothesis: Multiple sclerosis is caused by three-hits, strictly in order, in genetically susceptible persons. <i>Mult Scler Relat Disord.</i> 2018; <b>24</b>: 157–174. <a target=xrefwindow id=d5420e3117 href="http://www.ncbi.nlm.nih.gov/pubmed/30015080">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3120 href="https://doi.org/10.1016/j.msard.2018.06.014">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735120668">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d5420e3139 class=n-a></a>Giovannoni G, Cutter G, Sormani MP, <i> et al.</i>: Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. <i>Mult Scler Relat Disord.</i> 2017; <b>12</b>: 70–78. <a target=xrefwindow id=d5420e3150 href="http://www.ncbi.nlm.nih.gov/pubmed/28283111">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3153 href="https://doi.org/10.1016/j.msard.2017.01.007">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733479912"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e3162 class=n-a></a>Faissner S, Gold R: Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010. <i>CNS Drugs.</i> 2018; <b>32</b>(3): 269–287. <a target=xrefwindow id=d5420e3170 href="http://www.ncbi.nlm.nih.gov/pubmed/29600441">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3173 href="https://doi.org/10.1007/s40263-018-0488-6">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733479912">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733259866"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e3191 class=n-a></a>Mulero P, Midaglia L, Montalban X: Ocrelizumab: a new milestone in multiple sclerosis therapy. <i>Ther Adv Neurol Disord.</i> 2018; <b>11</b>: 1756286418773025. <a target=xrefwindow id=d5420e3199 href="http://www.ncbi.nlm.nih.gov/pubmed/29774057">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3202 href="https://doi.org/10.1177/1756286418773025">Publisher Full Text </a> | <a target=xrefwindow id=d5420e3205 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5952271">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733259866">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727132301"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e3223 class=n-a></a>Hauser SL, Bar-Or A, Comi G, <i> et al.</i>: Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. <i>N Engl J Med.</i> 2017; <b>376</b>(3): 221–234. <a target=xrefwindow id=d5420e3234 href="http://www.ncbi.nlm.nih.gov/pubmed/28002679">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3237 href="https://doi.org/10.1056/NEJMoa1601277">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727132301">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732415316"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e3255 class=n-a></a>Granqvist M, Boremalm M, Poorghobad A, <i> et al.</i>: Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis. <i>JAMA Neurol.</i> 2018; <b>75</b>(3): 320–327. <a target=xrefwindow id=d5420e3266 href="http://www.ncbi.nlm.nih.gov/pubmed/29309484">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3269 href="https://doi.org/10.1001/jamaneurol.2017.4011">Publisher Full Text </a> | <a target=xrefwindow id=d5420e3273 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5885857">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732415316">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731222139"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e3291 class=n-a></a>Patsopoulos N, Baranzini SE, Santaniello A, <i> et al.</i>: The Multiple Sclerosis Genomic Map: Role of peripheral immune cells and resident microglia in susceptibility. <i>bioRxiv.</i> 2017. <a target=xrefwindow id=d5420e3299 href="https://doi.org/10.1101/143933">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731222139">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d5420e3318 class=n-a></a>International Multiple Sclerosis Genetics Consortium (IMSGC), Beecham AH, Patsopoulos NA, <i> et al.</i>: Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. <i>Nat Genet.</i> 2013; <b>45</b>(11): 1353–1360. <a target=xrefwindow id=d5420e3329 href="http://www.ncbi.nlm.nih.gov/pubmed/24076602">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3332 href="https://doi.org/10.1038/ng.2770">Publisher Full Text </a> | <a target=xrefwindow id=d5420e3336 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3832895">Free Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d5420e3345 class=n-a></a>Afrasiabi A, Parnell GP, Fewings N, <i> et al.</i>: Genetic evidence that the latency III stage of Epstein-Barr Virus infection is a therapeutic target for Multiple Sclerosis. <i>bioRxiv.</i> 2018; 390609. <a target=xrefwindow id=d5420e3353 href="https://doi.org/10.1101/390609">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d5420e3362 class=n-a></a>Berge T, Leikfoss IS, Brorson IS, <i> et al.</i>: The multiple sclerosis susceptibility genes <i>TAGAP</i> and <i>IL2RA</i> are regulated by vitamin D in CD4+ T cells. <i>Genes Immun.</i> 2016; <b>17</b>(2): 118–127. <a target=xrefwindow id=d5420e3380 href="http://www.ncbi.nlm.nih.gov/pubmed/26765264">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3383 href="https://doi.org/10.1038/gene.2015.61">Publisher Full Text </a> | <a target=xrefwindow id=d5420e3386 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4783434">Free Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d5420e3395 class=n-a></a>Zhou Y, Zhu G, Charlesworth JC, <i> et al.</i>: Genetic loci for Epstein-Barr virus nuclear antigen-1 are associated with risk of multiple sclerosis. <i>Mult Scler.</i> 2016; <b>22</b>(13): 1655–1664. <a target=xrefwindow id=d5420e3406 href="http://www.ncbi.nlm.nih.gov/pubmed/26819262">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3409 href="https://doi.org/10.1177/1352458515626598">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d5420e3418 class=n-a></a>Parnell GP, Gatt PN, Krupa M, <i> et al.</i>: The autoimmune disease-associated transcription factors EOMES and TBX21 are dysregulated in multiple sclerosis and define a molecular subtype of disease. <i>Clin Immunol.</i> 2014; <b>151</b>(1): 16–24. <a target=xrefwindow id=d5420e3429 href="http://www.ncbi.nlm.nih.gov/pubmed/24495857">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3432 href="https://doi.org/10.1016/j.clim.2014.01.003">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d5420e3441 class=n-a></a>Khankhanian P, Cozen W, Himmelstein DS, <i> et al.</i>: Meta-analysis of genome-wide association studies reveals genetic overlap between Hodgkin lymphoma and multiple sclerosis. <i>Int J Epidemiol.</i> 2016; <b>45</b>(3): 728–740. <a target=xrefwindow id=d5420e3452 href="http://www.ncbi.nlm.nih.gov/pubmed/26971321">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3455 href="https://doi.org/10.1093/ije/dyv364">Publisher Full Text </a> | <a target=xrefwindow id=d5420e3459 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5005944">Free Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d5420e3469 class=n-a></a>Yenamandra SP, Hellman U, Kempkes B, <i> et al.</i>: Epstein-Barr virus encoded EBNA-3 binds to vitamin D receptor and blocks activation of its target genes. <i>Cell Mol Life Sci.</i> 2010; <b>67</b>(24): 4249–4256. <a target=xrefwindow id=d5420e3480 href="http://www.ncbi.nlm.nih.gov/pubmed/20593215">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3483 href="https://doi.org/10.1007/s00018-010-0441-4">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732563877"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e3492 class=n-a></a>Trier N, Izarzugaza J, Chailyan A, <i> et al.</i>: Human MHC-II with Shared Epitope Motifs Are Optimal Epstein-Barr Virus Glycoprotein 42 Ligands-Relation to Rheumatoid Arthritis. <i>Int J Mol Sci.</i> 2018; <b>19</b>(1): pii: E317. <a target=xrefwindow id=d5420e3503 href="http://www.ncbi.nlm.nih.gov/pubmed/29361739">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3506 href="https://doi.org/10.3390/ijms19010317">Publisher Full Text </a> | <a target=xrefwindow id=d5420e3510 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5796260">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732563877">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d5420e3528 class=n-a></a>Sheik-Ali S: Infectious mononucleosis and multiple sclerosis - Updated review on associated risk. <i>Mult Scler Relat Disord.</i> 2017; <b>14</b>: 56–59. <a target=xrefwindow id=d5420e3536 href="http://www.ncbi.nlm.nih.gov/pubmed/28619433">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3539 href="https://doi.org/10.1016/j.msard.2017.02.019">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732415467"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e3548 class=n-a></a>Dolei A: The aliens inside us: HERV-W endogenous retroviruses and multiple sclerosis. <i>Mult Scler.</i> 2018; <b>24</b>(1): 42–47. <a target=xrefwindow id=d5420e3556 href="http://www.ncbi.nlm.nih.gov/pubmed/29307292">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3559 href="https://doi.org/10.1177/1352458517737370">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732415467">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d5420e3577 class=n-a></a>'t Hart BA, Jagessar SA, Haanstra K, <i> et al.</i>: The Primate EAE Model Points at EBV-Infected B Cells as a Preferential Therapy Target in Multiple Sclerosis. <i>Front Immunol.</i> 2013; <b>4</b>: 145. <a target=xrefwindow id=d5420e3588 href="http://www.ncbi.nlm.nih.gov/pubmed/23781220">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3591 href="https://doi.org/10.3389/fimmu.2013.00145">Publisher Full Text </a> | <a target=xrefwindow id=d5420e3595 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3680746">Free Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d5420e3604 class=n-a></a>Pakpoor J, Disanto G, Gerber JE, <i> et al.</i>: The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. <i>Mult Scler.</i> 2013; <b>19</b>(2): 162–166. <a target=xrefwindow id=d5420e3615 href="http://www.ncbi.nlm.nih.gov/pubmed/22740437">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3618 href="https://doi.org/10.1177/1352458512449682">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d5420e3628 class=n-a></a>Munger KL, Fitzgerald KC, Freedman MS, <i> et al.</i>: No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. <i>Neurology.</i> 2015; <b>85</b>(19): 1694–1701. <a target=xrefwindow id=d5420e3639 href="http://www.ncbi.nlm.nih.gov/pubmed/26453645">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3642 href="https://doi.org/10.1212/WNL.0000000000002099">Publisher Full Text </a> | <a target=xrefwindow id=d5420e3646 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4653109">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d5420e3655 class=n-a></a>Salzer J, Myhr KM: Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: no. <i>Mult Scler.</i> 2013; <b>19</b>(13): 1692–1693. <a target=xrefwindow id=d5420e3663 href="http://www.ncbi.nlm.nih.gov/pubmed/24218487">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3666 href="https://doi.org/10.1177/1352458513507625">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d5420e3675 class=n-a></a>Kudo LC, Parfenova L, Ren G, <i> et al.</i>: Puromycin-sensitive aminopeptidase (PSA/NPEPPS) impedes development of neuropathology in hPSA/TAU<sup>P301L</sup> double-transgenic mice. <i>Hum Mol Genet.</i> 2011; <b>20</b>(9): 1820–1833. <a target=xrefwindow id=d5420e3689 href="http://www.ncbi.nlm.nih.gov/pubmed/21320871">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3693 href="https://doi.org/10.1093/hmg/ddr065">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d5420e3702 class=n-a></a>Ren G, Ma Z, Hui M, <i> et al.</i>: Cu, Zn-superoxide dismutase 1 (SOD1) is a novel target of Puromycin-sensitive aminopeptidase (PSA/NPEPPS): PSA/NPEPPS is a possible modifier of amyotrophic lateral sclerosis. <i>Mol Neurodegener.</i> 2011; <b>6</b>: 29. <a target=xrefwindow id=d5420e3713 href="http://www.ncbi.nlm.nih.gov/pubmed/21548977">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3716 href="https://doi.org/10.1186/1750-1326-6-29">Publisher Full Text </a> | <a target=xrefwindow id=d5420e3720 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3113298">Free Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732240908"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e3729 class=n-a></a>Fard MK, van der Meer F, Sánchez P, <i> et al.</i>: BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions. <i>Sci Transl Med.</i> 2017; <b>9</b>(419): pii: eaam7816. <a target=xrefwindow id=d5420e3740 href="http://www.ncbi.nlm.nih.gov/pubmed/29212715">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3743 href="https://doi.org/10.1126/scitranslmed.aam7816">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732240908">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d5420e3761 class=n-a></a>Ishimoto T, Ninomiya K, Inoue R, <i> et al.</i>: Mice lacking BCAS1, a novel myelin-associated protein, display hypomyelination, schizophrenia-like abnormal behaviors, and upregulation of inflammatory genes in the brain. <i>Glia.</i> 2017; <b>65</b>(5): 727–739. <a target=xrefwindow id=d5420e3772 href="http://www.ncbi.nlm.nih.gov/pubmed/28230289">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3775 href="https://doi.org/10.1002/glia.23129">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d5420e3785 class=n-a></a>Thangaraj MP, Furber KL, Gan JK, <i> et al.</i>: RNA-binding Protein Quaking Stabilizes <i>Sirt2</i> mRNA during Oligodendroglial Differentiation. <i>J Biol Chem.</i> 2017; <b>292</b>(13): 5166–5182. <a target=xrefwindow id=d5420e3799 href="http://www.ncbi.nlm.nih.gov/pubmed/28188285">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3803 href="https://doi.org/10.1074/jbc.M117.775544">Publisher Full Text </a> | <a target=xrefwindow id=d5420e3806 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5392665">Free Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/720473558"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e3815 class=n-a></a>Fischer MT, Sharma R, Lim JL, <i> et al.</i>: NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. <i>Brain.</i> 2012; <b>135</b>(Pt 3): 886–899. <a target=xrefwindow id=d5420e3826 href="http://www.ncbi.nlm.nih.gov/pubmed/22366799">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3829 href="https://doi.org/10.1093/brain/aws012">Publisher Full Text </a> | <a target=xrefwindow id=d5420e3833 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3286337">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/720473558">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d5420e3851 class=n-a></a>Olojo RO, Ziman AP, Hernández-Ochoa EO, <i> et al.</i>: Mice null for calsequestrin 1 exhibit deficits in functional performance and sarcoplasmic reticulum calcium handling. <i>PLoS One.</i> 2011; <b>6</b>(12): e27036. <a target=xrefwindow id=d5420e3862 href="http://www.ncbi.nlm.nih.gov/pubmed/22164205">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3865 href="https://doi.org/10.1371/journal.pone.0027036">Publisher Full Text </a> | <a target=xrefwindow id=d5420e3869 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3229475">Free Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730254157"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e3878 class=n-a></a>Wang Q, Chuikov S, Taitano S, <i> et al.</i>: Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway. <i>Int J Mol Sci.</i> 2015; <b>16</b>(6): 13885–13907. <a target=xrefwindow id=d5420e3889 href="http://www.ncbi.nlm.nih.gov/pubmed/26090715">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3892 href="https://doi.org/10.3390/ijms160613885">Publisher Full Text </a> | <a target=xrefwindow id=d5420e3896 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4490529">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730254157">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d5420e3914 class=n-a></a>Warne J, Pryce G, Hill JM, <i> et al.</i>: Selective Inhibition of the Mitochondrial Permeability Transition Pore Protects against Neurodegeneration in Experimental Multiple Sclerosis. <i>J Biol Chem.</i> 2016; <b>291</b>(9): 4356–4373. <a target=xrefwindow id=d5420e3925 href="http://www.ncbi.nlm.nih.gov/pubmed/26679998">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3928 href="https://doi.org/10.1074/jbc.M115.700385">Publisher Full Text </a> | <a target=xrefwindow id=d5420e3932 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4813465">Free Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732986114"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e3941 class=n-a></a>Cervantes-Gracia K, Husi H: Integrative analysis of Multiple Sclerosis using a systems biology approach. <i>Sci Rep.</i> 2018; <b>8</b>(1): 5633. <a target=xrefwindow id=d5420e3949 href="http://www.ncbi.nlm.nih.gov/pubmed/29618802">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3952 href="https://doi.org/10.1038/s41598-018-24032-8">Publisher Full Text </a> | <a target=xrefwindow id=d5420e3955 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5884799">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732986114">F1000 Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718675053"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e3974 class=n-a></a>Wager TT, Hou X, Verhoest PR, <i> et al.</i>: Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. <i>Acs Chem Neurosci.</i> 2010; <b>1</b>(6): 435–449. <a target=xrefwindow id=d5420e3985 href="http://www.ncbi.nlm.nih.gov/pubmed/22778837">PubMed Abstract </a> | <a target=xrefwindow id=d5420e3988 href="https://doi.org/10.1021/cn100008c">Publisher Full Text </a> | <a target=xrefwindow id=d5420e3992 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3368654">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718675053">F1000 Recommendation</a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d5420e4010 class=n-a></a>Christensen LF, Broom AD, Robins MJ, <i> et al.</i>: Synthesis and biological activity of selected 2,6-disubstituted-(2-deoxy- -and- -D-erythro-pentofuranosyl)purines. <i>J Med Chem.</i> 1972; <b>15</b>(7): 735–9. <a target=xrefwindow id=d5420e4021 href="http://www.ncbi.nlm.nih.gov/pubmed/4625489">PubMed Abstract </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d5420e4030 class=n-a></a>Bradford KL, Moretti FA, Carbonaro-Sarracino DA, <i> et al.</i>: Adenosine Deaminase (ADA)-Deficient Severe Combined Immune Deficiency (SCID): Molecular Pathogenesis and Clinical Manifestations. <i>J Clin Immunol.</i> 2017; <b>37</b>(7): 626–637. <a target=xrefwindow id=d5420e4041 href="http://www.ncbi.nlm.nih.gov/pubmed/28842866">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4044 href="https://doi.org/10.1007/s10875-017-0433-3">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d5420e4053 class=n-a></a>Carson DA, Kaye J, Matsumoto S, <i> et al.</i>: Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines. <i>Proc Natl Acad Sci U S A.</i> 1979; <b>76</b>(5): 2430–2433. <a target=xrefwindow id=d5420e4064 href="http://www.ncbi.nlm.nih.gov/pubmed/313056">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4067 href="http://www.ncbi.nlm.nih.gov/pmc/articles/383615">Free Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d5420e4076 class=n-a></a>Giovannoni G: Cladribine to Treat Relapsing Forms of Multiple Sclerosis. <i>Neurotherapeutics.</i> 2017; <b>14</b>(4): 874–887. <a target=xrefwindow id=d5420e4084 href="http://www.ncbi.nlm.nih.gov/pubmed/29168160">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4087 href="https://doi.org/10.1007/s13311-017-0573-4">Publisher Full Text </a> | <a target=xrefwindow id=d5420e4090 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5722776">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d5420e4099 class=n-a></a>Kawasaki H, Carrera CJ, Piro LD, <i> et al.</i>: Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. <i>Blood.</i> 1993; <b>81</b>(3): 597–601. <a target=xrefwindow id=d5420e4110 href="http://www.ncbi.nlm.nih.gov/pubmed/8094016">PubMed Abstract </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d5420e4120 class=n-a></a>Liliemark J: The clinical pharmacokinetics of cladribine. <i>Clin Pharmacokinet.</i> 1997; <b>32</b>(2): 120–131. <a target=xrefwindow id=d5420e4128 href="http://www.ncbi.nlm.nih.gov/pubmed/9068927">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4131 href="https://doi.org/10.2165/00003088-199732020-00003">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d5420e4140 class=n-a></a>Scheible H, Laisney M, Wimmer E, <i> et al.</i>: Comparison of the <i>in vitro</i> and <i>in vivo</i> metabolism of Cladribine (Leustatin, Movectro) in animals and human. <i>Xenobiotica.</i> 2013; <b>43</b>(12): 1084–1094. <a target=xrefwindow id=d5420e4158 href="http://www.ncbi.nlm.nih.gov/pubmed/23627543">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4161 href="https://doi.org/10.3109/00498254.2013.791762">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d5420e4170 class=n-a></a>Leist TP, Weissert R: Cladribine: mode of action and implications for treatment of multiple sclerosis. <i>Clin Neuropharmacol.</i> 2011; <b>34</b>(1): 28–35. <a target=xrefwindow id=d5420e4178 href="http://www.ncbi.nlm.nih.gov/pubmed/21242742">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4181 href="https://doi.org/10.1097/WNF.0b013e318204cd90">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d5420e4190 class=n-a></a>Giovannoni G, Comi G, Cook S, <i> et al.</i>: A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. <i>N Engl J Med.</i> 2010; <b>362</b>(5): 416–426. <a target=xrefwindow id=d5420e4201 href="http://www.ncbi.nlm.nih.gov/pubmed/20089960">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4204 href="https://doi.org/10.1056/NEJMoa0902533">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d5420e4213 class=n-a></a>Merck: Cladribine Tablets Receives Positive CHMP Opinion for Treatment of Relapsing Forms of Multiple Sclerosis. In Mavenclad (Cladribine tablets) has received a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). 2017. <a target=xrefwindow id=d5420e4215 href="https://www.merckgroup.com/en/news/mavenclad-chmp-06-23-2017.html">Reference Source</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d5420e4224 class=n-a></a>Braun-Sand SB, Peetz M: Inosine monophosphate dehydrogenase as a target for antiviral, anticancer, antimicrobial and immunosuppressive therapeutics. <i>Future Med Chem.</i> 2010; <b>2</b>(1): 81–92. <a target=xrefwindow id=d5420e4232 href="http://www.ncbi.nlm.nih.gov/pubmed/21426047">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4235 href="https://doi.org/10.4155/fmc.09.147">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d5420e4245 class=n-a></a>Xiao Y, Huang J, Luo H, <i> et al.</i>: Mycophenolate mofetil for relapsing-remitting multiple sclerosis. <i>Cochrane Database Syst Rev.</i> 2014; (2): CD010242. <a target=xrefwindow id=d5420e4253 href="http://www.ncbi.nlm.nih.gov/pubmed/24505016">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4256 href="https://doi.org/10.1002/14651858.CD010242.pub2">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718013011"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e4265 class=n-a></a>Michel L, Vukusic S, De Seze J, <i> et al.</i>: Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients. <i>J Neurol Neurosurg Psychiatry.</i> 2014; <b>85</b>(3): 279–283. <a target=xrefwindow id=d5420e4276 href="http://www.ncbi.nlm.nih.gov/pubmed/23704316">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4279 href="https://doi.org/10.1136/jnnp-2013-305298">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718013011">F1000 Recommendation</a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d5420e4297 class=n-a></a>Chen L, Wilson D, Jayaram HN, <i> et al.</i>: Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment. <i>J Med Chem.</i> 2007; <b>50</b>(26): 6685–6691. <a target=xrefwindow id=d5420e4308 href="http://www.ncbi.nlm.nih.gov/pubmed/18038969">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4311 href="https://doi.org/10.1021/jm070864w">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d5420e4320 class=n-a></a>Eickenberg S, Mickholz E, Jung E, <i> et al.</i>: Mycophenolic acid counteracts B cell proliferation and plasmablast formation in patients with systemic lupus erythematosus. <i>Arthritis Res Ther.</i> 2012; <b>14</b>(3): R110. <a target=xrefwindow id=d5420e4331 href="http://www.ncbi.nlm.nih.gov/pubmed/22571761">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4334 href="https://doi.org/10.1186/ar3835">Publisher Full Text </a> | <a target=xrefwindow id=d5420e4338 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4060361">Free Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d5420e4347 class=n-a></a>Pua KH, Stiles DT, Sowa ME, <i> et al.</i>: IMPDH2 Is an Intracellular Target of the Cyclophilin A and Sanglifehrin A Complex. <i>Cell Rep.</i> 2017; <b>18</b>(2): 432–442. <a target=xrefwindow id=d5420e4358 href="http://www.ncbi.nlm.nih.gov/pubmed/28076787">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4361 href="https://doi.org/10.1016/j.celrep.2016.12.030">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d5420e4370 class=n-a></a>Liao LX, Song XM, Wang LC, <i> et al.</i>: Highly selective inhibition of IMPDH2 provides the basis of antineuroinflammation therapy. <i>Proc Natl Acad Sci U S A.</i> 2017; <b>114</b>(29): E5986–E5994. <a target=xrefwindow id=d5420e4381 href="http://www.ncbi.nlm.nih.gov/pubmed/28674004">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4384 href="https://doi.org/10.1073/pnas.1706778114">Publisher Full Text </a> | <a target=xrefwindow id=d5420e4388 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5530702">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d5420e4398 class=n-a></a>Bar-Or A: Teriflunomide (Aubagio®) for the treatment of multiple sclerosis. <i>Exp Neurol.</i> 2014; <b>262</b>(Pt A): 57–65. <a target=xrefwindow id=d5420e4406 href="http://www.ncbi.nlm.nih.gov/pubmed/24925677">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4409 href="https://doi.org/10.1016/j.expneurol.2014.06.005">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d5420e4418 class=n-a></a>Li L, Liu JC, Delohery T, <i> et al.</i>: The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells <i>in vitro</i>. <i>J Neuroimmunol.</i> 2013; <b>265</b>(1–2): 82–90. <a target=xrefwindow id=d5420e4432 href="http://www.ncbi.nlm.nih.gov/pubmed/24182769">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4436 href="https://doi.org/10.1016/j.jneuroim.2013.10.003">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d5420e4445 class=n-a></a>Schwartz R, Davidson T: Pharmacology, pharmacokinetics, and practical applications of bortezomib. <i>Oncology (Williston Park).</i> 2004; <b>18</b>(14 Suppl 11): 14–21. <a target=xrefwindow id=d5420e4453 href="http://www.ncbi.nlm.nih.gov/pubmed/15688598">PubMed Abstract </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d5420e4462 class=n-a></a>Demo SD, Kirk CJ, Aujay MA, <i> et al.</i>: Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. <i>Cancer Res.</i> 2007; <b>67</b>(13): 6383–6391. <a target=xrefwindow id=d5420e4473 href="http://www.ncbi.nlm.nih.gov/pubmed/17616698">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4476 href="https://doi.org/10.1158/0008-5472.CAN-06-4086">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d5420e4485 class=n-a></a>Goldwirt L, Beccaria K, Ple A, <i> et al.</i>: Ibrutinib brain distribution: a preclinical study. <i>Cancer Chemother Pharmacol.</i> 2018; <b>81</b>(4): 783–789. <a target=xrefwindow id=d5420e4496 href="http://www.ncbi.nlm.nih.gov/pubmed/29476222">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4499 href="https://doi.org/10.1007/s00280-018-3546-3">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d5420e4508 class=n-a></a>Relations SM: Sanofi, Principia agree to develop multiple sclerosis drug candidate. 2017. <a target=xrefwindow id=d5420e4510 href="https://globenewswire.com/news-release/2017/11/09/1178445/0/en/Sanofi-Principia-agree-to-develop-multiple-sclerosis-drug-candidate.html">Reference Source</a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d5420e4520 class=n-a></a>Melao A: Potential B-cell targeting oral MS treatment, PRN2246, shows ability to reach brain in phase 1 study. In <i>Multiple Sclerosis News Today</i>. 2018. <a target=xrefwindow id=d5420e4525 href="https://multiplesclerosisnewstoday.com/2018/08/02/potential-b-cell-trageting-ms-therapy-by-principia-prn2246-seen-to-reach-brain-in-phase-1-study/">Reference Source</a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d5420e4534 class=n-a></a>Janssens A: Ibrutinib and idelalisib, the B-cell receptor antagonists available for use in daily clinical practice. <i>Belg J Hematol.</i> 2015; <b>6</b>: 216–224. </span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d5420e4549 class=n-a></a>Zhao M, Zhou P, Yu J, <i> et al.</i>: The tissue distribution and excretion study of paeoniflorin-6'-O-benzene sulfonate (CP-25) in rats. <i>Inflammopharmacology.</i> 2018. <a target=xrefwindow id=d5420e4557 href="http://www.ncbi.nlm.nih.gov/pubmed/29524003">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4560 href="https://doi.org/10.1007/s10787-018-0463-3">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733624548"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e4569 class=n-a></a>Terranova N, Hicking C, Dangond F, <i> et al.</i>: Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis. <i>Clin Pharmacokinet.</i> 2018. <a target=xrefwindow id=d5420e4577 href="http://www.ncbi.nlm.nih.gov/pubmed/29992396">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4580 href="https://doi.org/10.1007/s40262-018-0693-y">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733624548">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730140185"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e4598 class=n-a></a>De Stefano N, Giorgio A, Battaglini M, <i> et al.</i>: Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. <i>Mult Scler.</i> 2018; <b>24</b>(2): 222–226. <a target=xrefwindow id=d5420e4609 href="http://www.ncbi.nlm.nih.gov/pubmed/28140753">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4612 href="https://doi.org/10.1177/1352458517690269">Publisher Full Text </a> | <a target=xrefwindow id=d5420e4616 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5818021">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730140185">F1000 Recommendation</a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d5420e4634 class=n-a></a>Ali S, Paracha N, Cook S, <i> et al.</i>: Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study. <i>Clin Drug Investig.</i> 2012; <b>32</b>(1): 15–27. <a target=xrefwindow id=d5420e4645 href="http://www.ncbi.nlm.nih.gov/pubmed/22017519">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4648 href="https://doi.org/10.2165/11593310-000000000-00000">Publisher Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d5420e4658 class=n-a></a>Freedman MS, Leist TP, Comi G, <i> et al.</i>: The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study. <i>Mult Scler J Exp Transl Clin.</i> 2017; <b>3</b>(4): 2055217317732802. <a target=xrefwindow id=d5420e4669 href="http://www.ncbi.nlm.nih.gov/pubmed/29051829">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4672 href="https://doi.org/10.1177/2055217317732802">Publisher Full Text </a> | <a target=xrefwindow id=d5420e4676 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5637982">Free Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d5420e4685 class=n-a></a>Leist TP, Comi G, Cree BA, <i> et al.</i>: Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. <i>Lancet Neurol.</i> 2014; <b>13</b>(3): 257–267. <a target=xrefwindow id=d5420e4696 href="http://www.ncbi.nlm.nih.gov/pubmed/24502830">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4699 href="https://doi.org/10.1016/S1474-4422(14)70005-5">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d5420e4708 class=n-a></a>Montalban X, Leist TP, Cohen BA, <i> et al.</i>: Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study. <i>Neurol Neuroimmunol Neuroinflamm.</i> 2018; <b>5</b>: e477. <a target=xrefwindow id=d5420e4719 href="https://doi.org/10.1212/NXI.0000000000000477">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d5420e4728 class=n-a></a>Steininger C: Novel therapies for cytomegalovirus disease. <i>Recent Pat Antiinfect Drug Discov.</i> 2007; <b>2</b>(1): 53–72. <a target=xrefwindow id=d5420e4736 href="http://www.ncbi.nlm.nih.gov/pubmed/18221163">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4739 href="https://doi.org/10.2174/157489107779561634">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d5420e4748 class=n-a></a>Ziemssen T, Neuhaus O, Hohlfeld R: Risk-benefit assessment of glatiramer acetate in multiple sclerosis. <i>Drug Saf.</i> 2001; <b>24</b>(13): 979–990. <a target=xrefwindow id=d5420e4756 href="http://www.ncbi.nlm.nih.gov/pubmed/11735654">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4759 href="https://doi.org/10.2165/00002018-200124130-00005">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725398947"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e4768 class=n-a></a>Brennan MS, Matos MF, Li B, <i> et al.</i>: Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion <i>in vitro</i>. <i>PLoS One.</i> 2015; <b>10</b>(3): e0120254. <a target=xrefwindow id=d5420e4782 href="http://www.ncbi.nlm.nih.gov/pubmed/25793262">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4786 href="https://doi.org/10.1371/journal.pone.0120254">Publisher Full Text </a> | <a target=xrefwindow id=d5420e4789 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4368598">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725398947">F1000 Recommendation</a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726657561"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e4808 class=n-a></a>Kappos L, Arnold DL, Bar-Or A, <i> et al.</i>: Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet Neurol.</i> 2016; <b>15</b>(11): 1148–1159. <a target=xrefwindow id=d5420e4819 href="http://www.ncbi.nlm.nih.gov/pubmed/27543447">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4822 href="https://doi.org/10.1016/S1474-4422(16)30192-2">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726657561">F1000 Recommendation</a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d5420e4840 class=n-a></a>Tavares A, Barret O, Alagille D, <i> et al.</i>: Brain distribution of MS565, an imaging analogue of siponimod (BAF312), in non-human primates. <i>Eur J Neurol.</i> 2014; <b>21</b>: 504. <a target=xrefwindow id=d5420e4851 href="http://n.neurology.org/content/82/10_Supplement/P1.168">Reference Source</a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d5420e4860 class=n-a></a>Cohen JA, Arnold DL, Comi G, <i> et al.</i>: Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurol.</i> 2016; <b>15</b>(4): 373–381. <a target=xrefwindow id=d5420e4871 href="http://www.ncbi.nlm.nih.gov/pubmed/26879276">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4874 href="https://doi.org/10.1016/S1474-4422(16)00018-1">Publisher Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d5420e4883 class=n-a></a>Comi G, Arnold D, Cree B, <i> et al.</i>: Ozanimod Demonstrates Efficacy and Safety in a Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase 3 Trial of Relapsing Multiple Sclerosis (SUNBEAM). <i>Neurology.</i> 2018; <b>90</b>(15 Supplement). <a target=xrefwindow id=d5420e4894 href="http://n.neurology.org/content/90/15_Supplement/P3.396">Reference Source</a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726225435"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e4903 class=n-a></a>Scott FL, Clemons B, Brooks J, <i> et al.</i>: Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P<sub>1</sub>) and receptor-5 (S1P<sub>5</sub>) agonist with autoimmune disease-modifying activity. <i>Br J Pharmacol.</i> 2016; <b>173</b>(11): 1778–1792. <a target=xrefwindow id=d5420e4921 href="http://www.ncbi.nlm.nih.gov/pubmed/26990079">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4924 href="https://doi.org/10.1111/bph.13476">Publisher Full Text </a> | <a target=xrefwindow id=d5420e4927 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4867749">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726225435">F1000 Recommendation</a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d5420e4945 class=n-a></a>Bar-Or A, Zipp F, Scaramozza M, <i> et al.</i>: Effect of Ceralifimod (ONO-4641), a Sphingosine-1-Phosphate Receptor-1 and -5 Agonist, on Magnetic Resonance Imaging Outcomes in Patients with Multiple Sclerosis: Interim Results from the Extension of the DreaMS Study (P3.161). <i>Neurology.</i> 2014; <b>82</b>: P3.161. </span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d5420e4964 class=n-a></a>Olsson T, Boster A, Fernández Ó, <i> et al.</i>: Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. <i>J Neurol Neurosurg Psychiatry.</i> 2014; <b>85</b>(11): 1198–1208. <a target=xrefwindow id=d5420e4975 href="http://www.ncbi.nlm.nih.gov/pubmed/24659797">PubMed Abstract </a> | <a target=xrefwindow id=d5420e4978 href="https://doi.org/10.1136/jnnp-2013-307282">Publisher Full Text </a> | <a target=xrefwindow id=d5420e4982 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4215282">Free Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d5420e4991 class=n-a></a>Brueck W, Wegner C: Insight into the mechanism of laquinimod action. <i>J Neurol Sci.</i> 2011; <b>306</b>(1–2): 173–179. <a target=xrefwindow id=d5420e4999 href="http://www.ncbi.nlm.nih.gov/pubmed/21429524">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5002 href="https://doi.org/10.1016/j.jns.2011.02.019">Publisher Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d5420e5011 class=n-a></a>He D, Zhang C, Zhao X, <i> et al.</i>: Teriflunomide for multiple sclerosis. <i>Cochrane Database Syst Rev.</i> 2016; <b>3</b>: CD009882. <a target=xrefwindow id=d5420e5022 href="http://www.ncbi.nlm.nih.gov/pubmed/27003123">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5025 href="https://doi.org/10.1002/14651858.CD009882.pub3">Publisher Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d5420e5034 class=n-a></a>Confavreux C, O'Connor P, Comi G, <i> et al.</i>: Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurol.</i> 2014; <b>13</b>(3): 247–256. <a target=xrefwindow id=d5420e5045 href="http://www.ncbi.nlm.nih.gov/pubmed/24461574">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5048 href="https://doi.org/10.1016/S1474-4422(13)70308-9">Publisher Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d5420e5057 class=n-a></a>Green RM, Stewart DJ, Hugenholtz H, <i> et al.</i>: Human central nervous system and plasma pharmacology of mitoxantrone. <i>J Neurooncol.</i> 1988; <b>6</b>(1): 75–83. <a target=xrefwindow id=d5420e5068 href="http://www.ncbi.nlm.nih.gov/pubmed/3397768">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5071 href="https://doi.org/10.1007/BF00163544">Publisher Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d5420e5080 class=n-a></a>CHMP: Assessment report EMA/CHMP/425279/2013. Xeljanz, 2013. <a target=xrefwindow id=d5420e5082 href="https://www.ema.europa.eu/documents/assessment-report/xeljanz-epar-public-assessment-report_en-0.pdf">Reference Source</a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718634927"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e5092 class=n-a></a>Miller AE, Wolinsky JS, Kappos L, <i> et al.</i>: Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurol.</i> 2014; <b>13</b>(10): 977–986. <a target=xrefwindow id=d5420e5103 href="http://www.ncbi.nlm.nih.gov/pubmed/25192851">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5106 href="https://doi.org/10.1016/S1474-4422(14)70191-7">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718634927">F1000 Recommendation</a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d5420e5124 class=n-a></a>Gandoglia I, Ivaldi F, Laroni A, <i> et al.</i>: Teriflunomide treatment reduces B cells in patients with MS. <i>Neurol Neuroimmunol Neuroinflamm.</i> 2017; <b>4</b>(6): e403. <a target=xrefwindow id=d5420e5135 href="http://www.ncbi.nlm.nih.gov/pubmed/29082295">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5138 href="https://doi.org/10.1212/NXI.0000000000000403">Publisher Full Text </a> | <a target=xrefwindow id=d5420e5142 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5656406">Free Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735120669"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e5151 class=n-a></a>Ontaneda D, Nicholas J, Carraro M, <i> et al.</i>: Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US. <i>Mult Scler Relat Disord.</i> 2018; <b>27</b>: 101–111. <a target=xrefwindow id=d5420e5162 href="http://www.ncbi.nlm.nih.gov/pubmed/30368221">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5165 href="https://doi.org/10.1016/j.msard.2018.09.038">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735120669">F1000 Recommendation</a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d5420e5183 class=n-a></a>Limsakun T, Menguy-Vacheron F: Pharmacokinetics of Oral Teriflunomide, a Novel Oral Disease-Modifying Agent under Investigation for the Treatment of Multiple Sclerosis. <i>Neurology.</i> 2010; <b>74</b>: A415–A415. </span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d5420e5198 class=n-a></a>Bartlett RR: Immunopharmacological profile of HWA 486, a novel isoxazol derivative--II. <i>In vivo</i> immunomodulating effects differ from those of cyclophosphamide, prednisolone, or cyclosporin A. <i>Int J Immunopharmacol.</i> 1986; <b>8</b>(2): 199–204. <a target=xrefwindow id=d5420e5209 href="http://www.ncbi.nlm.nih.gov/pubmed/3486841">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5212 href="https://doi.org/10.1016/0192-0561(86)90059-7">Publisher Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d5420e5221 class=n-a></a>Aly L, Hemmer B, Korn T: From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis. <i>Curr Neuropharmacol.</i> 2017; <b>15</b>(6): 874–891. <a target=xrefwindow id=d5420e5229 href="http://www.ncbi.nlm.nih.gov/pubmed/27928949">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5232 href="https://doi.org/10.2174/1570159X14666161208151525">Publisher Full Text </a> | <a target=xrefwindow id=d5420e5235 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5652031">Free Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d5420e5245 class=n-a></a>Eschborni M, Klotz L, Lindner M, <i> et al.</i>: Teriflunomide modulates antigen-specific immune responses in an affinity-dependent fashion by inhibiting T cell metabolism. <i>Mult Scler J.</i> 2018; <b>24</b>: 675–676. <a target=xrefwindow id=d5420e5256 href="https://onlinelibrary.ectrims-congress.eu/ectrims/2018/ectrims-2018/229037/melanie.eschborn.teriflunomide.modulates.antigen-specific.immune.responses.in.html?f=menu=14*media=3*speaker=642345*browseby=8">Reference Source</a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d5420e5265 class=n-a></a>Pender MP, Csurhes PA, Smith C, <i> et al.</i>: Safety and clinical improvement in a phase I trial of autologous Epstein-Barr virus-specific T-cell therapy in patients with progressive multiple sclerosis. <i>Mult Scler J.</i> 2017; <b>23</b>: 401. <a target=xrefwindow id=d5420e5276 href="http://onlinelibrary.ectrims-congress.eu/ectrims/2017/ACTRIMS-ECTRIMS2017/200440/michael.p.pender.safety.and.clinical.improvement.in.a.phase.i.trial.of.html">Reference Source</a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734602434"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e5285 class=n-a></a>Pagano JS, Whitehurst CB, Andrei G: Antiviral Drugs for EBV. <i>Cancers (Basel).</i> 2018; <b>10</b>(6): pii: E197. <a target=xrefwindow id=d5420e5293 href="http://www.ncbi.nlm.nih.gov/pubmed/29899236">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5296 href="https://doi.org/10.3390/cancers10060197">Publisher Full Text </a> | <a target=xrefwindow id=d5420e5299 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6025560">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734602434">F1000 Recommendation</a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d5420e5317 class=n-a></a>Whitehurst CB, Sanders MK, Law M, <i> et al.</i>: Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase. <i>J Virol.</i> 2013; <b>87</b>(9): 5311–5315. <a target=xrefwindow id=d5420e5328 href="http://www.ncbi.nlm.nih.gov/pubmed/23449792">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5331 href="https://doi.org/10.1128/JVI.03505-12">Publisher Full Text </a> | <a target=xrefwindow id=d5420e5335 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3624302">Free Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d5420e5344 class=n-a></a>Papanicolaou G, Silveira FP, Langston A, <i> et al.</i>: Maribavir for Treatment of Cytomegalovirus (CMV) Infections Resistant or Refractory to Ganciclovir or Foscarnet in Hematopoietic Stem Cell Transplant (SCT) or Solid Organ Transplant (SOT) Recipients: A Randomized, Dose-Ranging, Double-Blind, Phase 2 Study. <i>Open Forum Infect Dis.</i> 2016; <b>3</b>(suppl_1): 78. <a target=xrefwindow id=d5420e5355 href="https://doi.org/10.1093/ofid/ofw194.13">Publisher Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d5420e5364 class=n-a></a>Winston DJ, Saliba F, Blumberg E, <i> et al.</i>: Efficacy and Safety of Maribavir Dosed at 100 mg Orally Twice Daily for the Prevention of Cytomegalovirus Disease in Liver Transplant Recipients: A Randomized, Double-Blind, Multicenter Controlled Trial (vol 12, pg 3021, 2012). <i>Am J Transplant.</i> 2013; <b>13</b>: 529. </span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d5420e5383 class=n-a></a>Coen N, Duraffour S, Naesens L, <i> et al.</i>: Evaluation of novel acyclic nucleoside phosphonates against human and animal gammaherpesviruses revealed an altered metabolism of cyclic prodrugs upon Epstein-Barr virus reactivation in P3HR-1 cells. <i>J Virol.</i> 2013; <b>87</b>(22): 12422–12432. <a target=xrefwindow id=d5420e5394 href="http://www.ncbi.nlm.nih.gov/pubmed/24027315">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5397 href="https://doi.org/10.1128/JVI.02231-13">Publisher Full Text </a> | <a target=xrefwindow id=d5420e5401 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3807898">Free Full Text </a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a name=d5420e5410 class=n-a></a>Coen N, Duraffour S, Topalis D, <i> et al.</i>: Spectrum of activity and mechanisms of resistance of various nucleoside derivatives against gammaherpesviruses. <i>Antimicrob Agents Chemother.</i> 2014; <b>58</b>(12): 7312–7323. <a target=xrefwindow id=d5420e5421 href="http://www.ncbi.nlm.nih.gov/pubmed/25267682">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5424 href="https://doi.org/10.1128/AAC.03957-14">Publisher Full Text </a> | <a target=xrefwindow id=d5420e5428 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4249563">Free Full Text </a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a name=d5420e5437 class=n-a></a>Coen N, Duraffour S, Haraguchi K, <i> et al.</i>: Antiherpesvirus activities of two novel 4'-thiothymidine derivatives, KAY-2-41 and KAH-39-149, are dependent on viral and cellular thymidine kinases. <i>Antimicrob Agents Chemother.</i> 2014; <b>58</b>(8): 4328–4340. <a target=xrefwindow id=d5420e5448 href="http://www.ncbi.nlm.nih.gov/pubmed/24820089">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5451 href="https://doi.org/10.1128/AAC.02825-14">Publisher Full Text </a> | <a target=xrefwindow id=d5420e5455 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4136010">Free Full Text </a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d5420e5464 class=n-a></a>Cohen JI: Epstein-barr virus vaccines. <i>Clin Transl Immunology.</i> 2015; 4(1): e32. <a target=xrefwindow id=d5420e5469 href="http://www.ncbi.nlm.nih.gov/pubmed/26131364">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5472 href="https://doi.org/10.1038/cti.2015.4">Publisher Full Text </a> | <a target=xrefwindow id=d5420e5475 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4478870">Free Full Text </a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733248603"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e5484 class=n-a></a>Zhao BC, Zhang X, Krummenacher C, <i> et al.</i>: Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model. <i>Front Immunol.</i> 2018; <b>9</b>: 932. <a target=xrefwindow id=d5420e5495 href="http://www.ncbi.nlm.nih.gov/pubmed/29765376">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5498 href="https://doi.org/10.3389/fimmu.2018.00932">Publisher Full Text </a> | <a target=xrefwindow id=d5420e5502 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5938345">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733248603">F1000 Recommendation</a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d5420e5520 class=n-a></a>Mc Guire C, Prinz M, Beyaert R, <i> et al.</i>: Nuclear factor kappa B (NF-κB) in multiple sclerosis pathology. <i>Trends Mol Med.</i> 2013; <b>19</b>(10): 604–613. <a target=xrefwindow id=d5420e5531 href="http://www.ncbi.nlm.nih.gov/pubmed/24007818">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5534 href="https://doi.org/10.1016/j.molmed.2013.08.001">Publisher Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d5420e5544 class=n-a></a>Kloetzel PM: The proteasome and MHC class I antigen processing. <i>Biochim Biophys Acta.</i> 2004; <b>1695</b>(1–3): 225–233. <a target=xrefwindow id=d5420e5552 href="http://www.ncbi.nlm.nih.gov/pubmed/15571818">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5555 href="https://doi.org/10.1016/j.bbamcr.2004.10.004">Publisher Full Text </a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d5420e5564 class=n-a></a>Cascio P, Oliva L, Cerruti F, <i> et al.</i>: Dampening Ab responses using proteasome inhibitors following <i>in vivo</i> B cell activation. <i>Eur J Immunol.</i> 2008; <b>38</b>(3): 658–667. <a target=xrefwindow id=d5420e5578 href="http://www.ncbi.nlm.nih.gov/pubmed/18253932">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5582 href="https://doi.org/10.1002/eji.200737743">Publisher Full Text </a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d5420e5591 class=n-a></a>Zhang C, Tian DC, Yang CS, <i> et al.</i>: Safety and Efficacy of Bortezomib in Patients With Highly Relapsing Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurol.</i> 2017; <b>74</b>(8): 1010–1012. <a target=xrefwindow id=d5420e5602 href="http://www.ncbi.nlm.nih.gov/pubmed/28692708">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5605 href="https://doi.org/10.1001/jamaneurol.2017.1336">Publisher Full Text </a> | <a target=xrefwindow id=d5420e5609 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5822186">Free Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d5420e5618 class=n-a></a>Alexander T, Sarfert R, Klotsche J, <i> et al.</i>: The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. <i>Ann Rheum Dis.</i> 2015; <b>74</b>(7): 1474–1478. <a target=xrefwindow id=d5420e5629 href="http://www.ncbi.nlm.nih.gov/pubmed/25710470">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5632 href="https://doi.org/10.1136/annrheumdis-2014-206016">Publisher Full Text </a> | <a target=xrefwindow id=d5420e5636 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4484251">Free Full Text </a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733126348"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e5645 class=n-a></a>Stockstill K, Doyle TM, Yan X, <i> et al.</i>: Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain. <i>J Exp Med.</i> 2018; <b>215</b>(5): 1301–1313. <a target=xrefwindow id=d5420e5656 href="http://www.ncbi.nlm.nih.gov/pubmed/29703731">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5659 href="https://doi.org/10.1084/jem.20170584">Publisher Full Text </a> | <a target=xrefwindow id=d5420e5663 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5940258">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733126348">F1000 Recommendation</a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a name=d5420e5681 class=n-a></a>Mulder A, Heidt S, Vergunst M, <i> et al.</i>: Proteasome inhibition profoundly affects activated human B cells. <i>Transplantation.</i> 2013; <b>95</b>(11): 1331–1337. <a target=xrefwindow id=d5420e5692 href="http://www.ncbi.nlm.nih.gov/pubmed/23624544">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5695 href="https://doi.org/10.1097/TP.0b013e3182911739">Publisher Full Text </a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d5420e5705 class=n-a></a>Puri KD, Di Paolo JA, Gold MR: B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies. <i>Int Rev Immunol.</i> 2013; <b>32</b>(4): 397–427. <a target=xrefwindow id=d5420e5713 href="http://www.ncbi.nlm.nih.gov/pubmed/23886342">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5716 href="https://doi.org/10.3109/08830185.2013.818140">Publisher Full Text </a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725996669"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e5725 class=n-a></a>Burger JA, Tedeschi A, Barr PM, <i> et al.</i>: Investigators R-. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>N Engl J Med.</i> 2015; <b>373</b>(25): 2425–2437. <a target=xrefwindow id=d5420e5736 href="http://www.ncbi.nlm.nih.gov/pubmed/26639149">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5739 href="https://doi.org/10.1056/NEJMoa1509388">Publisher Full Text </a> | <a target=xrefwindow id=d5420e5743 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4722809">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725996669">F1000 Recommendation</a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a name=d5420e5761 class=n-a></a>Treon S, Tripsas C, Meid K, <i> et al.</i>: Ibrutinib in Previously Treated Patients with Waldenstrom's Macroglobulinemia Is Highly Active, Produces Durable Responses, and Is Impacted by Myd88 and Cxcr4 Mutation Status. <i>Haematologica.</i> 2015; <b>100</b>: 311–311. </span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a name=d5420e5779 class=n-a></a>Merck AG: Merck Announces Positive Phase IIB Results for Evobrutinib in Relapsing Multiple Sclerosis. Merck AG; 2018. <a target=xrefwindow id=d5420e5781 href="https://www.merckgroup.com/content/dam/web/corporate/non-images/press-releases/2018/mar/en/Evobrutinib-Positive-Phase-IIb-Results-EN.pdf">Reference Source</a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a name=d5420e5790 class=n-a></a>Montalban X, Arnold DL, Weber MS, <i> et al.</i>: Primary analysis of a randomised, placebo-controlled, phase 2 study of the Bruton’s tyrosine kinase inhibitor evobrutinib (M2951) in patients with relapsing multiple sclerosis. In <i>34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)</i>. Berlin, Germany, SAGE; 2018. <a target=xrefwindow id=d5420e5798 href="http://onlinelibrary.ectrims-congress.eu/ectrims/2018/ectrims-2018/232075/xavier.montalban.primary.analysis.of.a.randomised.placebo-controlled.phase.2.html">Reference Source</a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/716597824"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e5807 class=n-a></a>Conley ME, Dobbs AK, Quintana AM, <i> et al.</i>: Agammaglobulinemia and absent B lineage cells in a patient lacking the p85α subunit of PI3K. <i>J Exp Med.</i> 2012; <b>209</b>(3): 463–470. <a target=xrefwindow id=d5420e5818 href="http://www.ncbi.nlm.nih.gov/pubmed/22351933">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5821 href="https://doi.org/10.1084/jem.20112533">Publisher Full Text </a> | <a target=xrefwindow id=d5420e5825 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3302225">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/716597824">F1000 Recommendation</a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a name=d5420e5844 class=n-a></a>Coutré SE, Barrientos JC, Brown JR, <i> et al.</i>: Management of adverse events associated with idelalisib treatment: expert panel opinion. <i>Leukemia Lymphoma.</i> 2015; <b>56</b>(10): 2779–2786. <a target=xrefwindow id=d5420e5855 href="http://www.ncbi.nlm.nih.gov/pubmed/25726955">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5858 href="https://doi.org/10.3109/10428194.2015.1022770">Publisher Full Text </a> | <a target=xrefwindow id=d5420e5862 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4732460">Free Full Text </a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a name=d5420e5871 class=n-a></a>Rickert RC, Jellusova J, Miletic AV: Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. <i>Immunol Rev.</i> 2011; <b>244</b>(1): 115–133. <a target=xrefwindow id=d5420e5879 href="http://www.ncbi.nlm.nih.gov/pubmed/22017435">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5882 href="https://doi.org/10.1111/j.1600-065X.2011.01067.x">Publisher Full Text </a> | <a target=xrefwindow id=d5420e5885 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3202302">Free Full Text </a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a name=d5420e5894 class=n-a></a>Krumbholz M, Theil D, Derfuss T, <i> et al.</i>: BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. <i>Journal of Experimental Medicine.</i> 2005; <b>201</b>(2): 195–200. <a target=xrefwindow id=d5420e5905 href="http://www.ncbi.nlm.nih.gov/pubmed/15642740">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5908 href="https://doi.org/10.1084/jem.20041674">Publisher Full Text </a> | <a target=xrefwindow id=d5420e5912 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2212784">Free Full Text </a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727555278"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e5921 class=n-a></a>Steri M, Orru V, Idda ML, <i> et al.</i>: Overexpression of the Cytokine BAFF and Autoimmunity Risk. <i>N Engl J Med.</i> 2017; <b>376</b>(17): 1615–1626. <a target=xrefwindow id=d5420e5932 href="http://www.ncbi.nlm.nih.gov/pubmed/28445677">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5935 href="https://doi.org/10.1056/NEJMoa1610528">Publisher Full Text </a> | <a target=xrefwindow id=d5420e5939 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5605835">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727555278">F1000 Recommendation</a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a name=d5420e5957 class=n-a></a>Yan D, Saito K, Ohmi Y, <i> et al.</i>: Paeoniflorin, a novel heat shock protein-inducing compound. <i>Cell Stress Chaperones.</i> 2004; <b>9</b>(4): 378–389. <a target=xrefwindow id=d5420e5968 href="http://www.ncbi.nlm.nih.gov/pubmed/15633296">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5971 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1065277">Free Full Text </a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a name=d5420e5980 class=n-a></a>Zhang F, Shu JL, Li Y, <i> et al.</i>: CP-25, a Novel Anti-inflammatory and Immunomodulatory Drug, Inhibits the Functions of Activated Human B Cells through Regulating BAFF and TNF-alpha Signaling and Comparative Efficacy with Biological Agents. <i>Front Pharmacol.</i> 2017; <b>8</b>: 933. <a target=xrefwindow id=d5420e5991 href="http://www.ncbi.nlm.nih.gov/pubmed/29311935">PubMed Abstract </a> | <a target=xrefwindow id=d5420e5994 href="https://doi.org/10.3389/fphar.2017.00933">Publisher Full Text </a> | <a target=xrefwindow id=d5420e5998 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5743740">Free Full Text </a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726738020"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e6008 class=n-a></a>Blewett MM, Xie JJ, Zaro BW, <i> et al.</i>: Chemical proteomic map of dimethyl fumarate-sensitive cysteines in primary human T cells. <i>Sci Signal.</i> 2016; <b>9</b>(445): rs10. <a target=xrefwindow id=d5420e6019 href="http://www.ncbi.nlm.nih.gov/pubmed/27625306">PubMed Abstract </a> | <a target=xrefwindow id=d5420e6022 href="https://doi.org/10.1126/scisignal.aaf7694">Publisher Full Text </a> | <a target=xrefwindow id=d5420e6026 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5068918">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726738020">F1000 Recommendation</a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732615801"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e6044 class=n-a></a>Mills EA, Ogrodnik MA, Plave A, <i> et al.</i>: Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis. <i>Front Neurol.</i> 2018; <b>9</b>: 5. <a target=xrefwindow id=d5420e6055 href="http://www.ncbi.nlm.nih.gov/pubmed/29410647">PubMed Abstract </a> | <a target=xrefwindow id=d5420e6058 href="https://doi.org/10.3389/fneur.2018.00005">Publisher Full Text </a> | <a target=xrefwindow id=d5420e6062 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5787128">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732615801">F1000 Recommendation</a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733321583"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e6080 class=n-a></a>Montes Diaz G, Fraussen J, Van Wijmeersch B, <i> et al.</i>: Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients. <i>Sci Rep.</i> 2018; <b>8</b>(1): 8194. <a target=xrefwindow id=d5420e6091 href="http://www.ncbi.nlm.nih.gov/pubmed/29844361">PubMed Abstract </a> | <a target=xrefwindow id=d5420e6094 href="https://doi.org/10.1038/s41598-018-26519-w">Publisher Full Text </a> | <a target=xrefwindow id=d5420e6098 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5974280">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733321583">F1000 Recommendation</a></span></li><li><a name=ref-135 class=n-a></a><span class=label>135. </span>&nbsp;<span class=citation><a name=d5420e6116 class=n-a></a>Schwartz DM, Kanno Y, Villarino A, <i> et al.</i>: JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. <i>Nat Rev Drug Discov.</i> 2017; <b>16</b>(12): 843–862. <a target=xrefwindow id=d5420e6127 href="http://www.ncbi.nlm.nih.gov/pubmed/29104284">PubMed Abstract </a> | <a target=xrefwindow id=d5420e6130 href="https://doi.org/10.1038/nrd.2017.201">Publisher Full Text </a></span></li><li><a name=ref-136 class=n-a></a><span class=label>136. </span>&nbsp;<span class=citation><a name=d5420e6139 class=n-a></a>Park SJ, Im DS: Sphingosine 1-Phosphate Receptor Modulators and Drug Discovery. <i>Biomol Ther (Seoul).</i> 2017; <b>25</b>(1): 80–90. <a target=xrefwindow id=d5420e6147 href="http://www.ncbi.nlm.nih.gov/pubmed/28035084">PubMed Abstract </a> | <a target=xrefwindow id=d5420e6150 href="https://doi.org/10.4062/biomolther.2016.160">Publisher Full Text </a> | <a target=xrefwindow id=d5420e6153 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5207465">Free Full Text </a></span></li><li><a name=ref-137 class=n-a></a><span class=label>137. </span>&nbsp;<span class=citation><a name=d5420e6162 class=n-a></a>Brinkmann V: FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. <i>Br J Pharmacol.</i> 2009; <b>158</b>(5): 1173–1182. <a target=xrefwindow id=d5420e6170 href="http://www.ncbi.nlm.nih.gov/pubmed/19814729">PubMed Abstract </a> | <a target=xrefwindow id=d5420e6173 href="https://doi.org/10.1111/j.1476-5381.2009.00451.x">Publisher Full Text </a> | <a target=xrefwindow id=d5420e6176 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2782328">Free Full Text </a></span></li><li><a name=ref-138 class=n-a></a><span class=label>138. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732846030"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e6186 class=n-a></a>Dong YF, Guo RB, Ji J, <i> et al.</i>: S1PR3 is essential for phosphorylated fingolimod to protect astrocytes against oxygen-glucose deprivation-induced neuroinflammation via inhibiting TLR2/4-NFκB signalling. <i>J Cell Mol Med.</i> 2018; <b>22</b>(6): 3159–3166. <a target=xrefwindow id=d5420e6197 href="http://www.ncbi.nlm.nih.gov/pubmed/29536648">PubMed Abstract </a> | <a target=xrefwindow id=d5420e6200 href="https://doi.org/10.1111/jcmm.13596">Publisher Full Text </a> | <a target=xrefwindow id=d5420e6204 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5980137">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732846030">F1000 Recommendation</a></span></li><li><a name=ref-139 class=n-a></a><span class=label>139. </span>&nbsp;<span class=citation> <a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732046430"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d5420e6222 class=n-a></a>Miyazaki Y, Niino M, Takahashi E, <i> et al.</i>: Fingolimod induces BAFF and expands circulating transitional B cells without activating memory B cells and plasma cells in multiple sclerosis. <i>Clin Immunol.</i> 2018; <b>187</b>: 95–101. <a target=xrefwindow id=d5420e6233 href="http://www.ncbi.nlm.nih.gov/pubmed/29079163">PubMed Abstract </a> | <a target=xrefwindow id=d5420e6236 href="https://doi.org/10.1016/j.clim.2017.10.009">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732046430">F1000 Recommendation</a></span></li><li><a name=ref-140 class=n-a></a><span class=label>140. </span>&nbsp;<span class=citation><a name=d5420e6254 class=n-a></a>Yoshii F, Moriya Y, Ohnuki T, <i> et al.</i>: Neurological safety of fingolimod: An updated review. <i>Clin Exp Neuroimmunol.</i> 2017; <b>8</b>(3): 233–243. <a target=xrefwindow id=d5420e6265 href="http://www.ncbi.nlm.nih.gov/pubmed/28932291">PubMed Abstract </a> | <a target=xrefwindow id=d5420e6268 href="https://doi.org/10.1111/cen3.12397">Publisher Full Text </a> | <a target=xrefwindow id=d5420e6272 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5575715">Free Full Text </a></span></li><li><a name=ref-141 class=n-a></a><span class=label>141. </span>&nbsp;<span class=citation><a name=d5420e6281 class=n-a></a>Brunmark C, Runström A, Ohlsson L, <i> et al.</i>: The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. <i>J Neuroimmunol.</i> 2002; <b>130</b>(1–2): 163–172. <a target=xrefwindow id=d5420e6292 href="http://www.ncbi.nlm.nih.gov/pubmed/12225898">PubMed Abstract </a> | <a target=xrefwindow id=d5420e6295 href="https://doi.org/10.1016/S0165-5728(02)00225-4">Publisher Full Text </a></span></li><li><a name=ref-142 class=n-a></a><span class=label>142. </span>&nbsp;<span class=citation><a name=d5420e6304 class=n-a></a>Wegner C, Stadelmann C, Pförtner R, <i> et al.</i>: Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. <i>J Neuroimmunol.</i> 2010; <b>227</b>(1–2): 133–143. <a target=xrefwindow id=d5420e6315 href="http://www.ncbi.nlm.nih.gov/pubmed/20684995">PubMed Abstract </a> | <a target=xrefwindow id=d5420e6318 href="https://doi.org/10.1016/j.jneuroim.2010.07.009">Publisher Full Text </a></span></li><li><a name=ref-143 class=n-a></a><span class=label>143. </span>&nbsp;<span class=citation><a name=d5420e6327 class=n-a></a>Varrin-Doyer M, Pekarek KL, Spencer CM, <i> et al.</i>: Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression. <i>Neurol Neuroimmunol Neuroinflamm.</i> 2016; <b>3</b>(5); e272. <a target=xrefwindow id=d5420e6338 href="http://www.ncbi.nlm.nih.gov/pubmed/27704036">PubMed Abstract </a> | <a target=xrefwindow id=d5420e6341 href="https://doi.org/10.1212/NXI.0000000000000272">Publisher Full Text </a> | <a target=xrefwindow id=d5420e6345 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5032667">Free Full Text </a></span></li><li><a name=ref-144 class=n-a></a><span class=label>144. </span>&nbsp;<span class=citation><a name=d5420e6355 class=n-a></a>Comi G, Jeffrey D, Kappos L, <i> et al.</i>: Oral Laquinimod Reduced Relapse Rate and Delayed Progression of Disability in Allegro, a Placebo-Controlled Phase III Trial for Relapsing-Remitting Multiple Sclerosis. <i>Neurology.</i> 2011; <b>77</b>: 200–201. </span></li><li><a name=ref-145 class=n-a></a><span class=label>145. </span>&nbsp;<span class=citation><a name=d5420e6373 class=n-a></a>Vollmer TL, Sorensen PS, Arnold DL, <i> et al.</i>: A placebo-controlled and active comparator phase III trial (BRAVO) for relapsing-remitting multiple sclerosis. <i>Mult Scler J.</i> 2011; <b>17</b>(10): S507–S508. <a target=xrefwindow id=d5420e6384 href="https://www.researchgate.net/publication/283689098_A_placebo-controlled_and_active_comparator_phase_III_trial_BRAVO_for_relapsing-remitting_multiple_sclerosis">Reference Source</a></span></li><li><a name=ref-146 class=n-a></a><span class=label>146. </span>&nbsp;<span class=citation><a name=d5420e6393 class=n-a></a>Comi G, Vollmer TL, Boyko A, <i> et al.</i>: CONCERTO: a placebo-controlled trial of oral laquinimod in patients with relapsing-remitting multiple sclerosis. <i>Mult Scler J.</i> 2017; <b>23</b>: 74–75. <a target=xrefwindow id=d5420e6404 href="http://onlinelibrary.ectrims-congress.eu/ectrims/2017/ACTRIMS-ECTRIMS2017/202596/giancarlo.comi.concerto.a.placebo-controlled.trial.of.oral.laquinimod.in.html">Reference Source</a></span></li><li><a name=ref-147 class=n-a></a><span class=label>147. </span>&nbsp;<span class=citation><a name=d5420e6413 class=n-a></a>Kaye J, Piryatinsky V, Birnberg T, <i> et al.</i>: Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor. <i>Proc Natl Acad Sci U S A.</i> 2016; <b>113</b>(41): E6145–E6152. <a target=xrefwindow id=d5420e6424 href="http://www.ncbi.nlm.nih.gov/pubmed/27671624">PubMed Abstract </a> | <a target=xrefwindow id=d5420e6427 href="https://doi.org/10.1073/pnas.1607843113">Publisher Full Text </a> | <a target=xrefwindow id=d5420e6431 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5068259">Free Full Text </a></span></li><li><a name=ref-148 class=n-a></a><span class=label>148. </span>&nbsp;<span class=citation><a name=d5420e6440 class=n-a></a>Toubi E, Nussbaum S, Staun-Ram E, <i> et al.</i>: Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis. <i>J Neuroimmunol.</i> 2012; <b>251</b>(1–2): 45–54. <a target=xrefwindow id=d5420e6451 href="http://www.ncbi.nlm.nih.gov/pubmed/22846497">PubMed Abstract </a> | <a target=xrefwindow id=d5420e6454 href="https://doi.org/10.1016/j.jneuroim.2012.07.003">Publisher Full Text </a></span></li><li><a name=ref-149 class=n-a></a><span class=label>149. </span>&nbsp;<span class=citation><a name=d5420e6463 class=n-a></a>Liu LF: DNA topoisomerase poisons as antitumor drugs. <i>Annu Rev Biochem.</i> 1989; <b>58</b>: 351–375. <a target=xrefwindow id=d5420e6471 href="http://www.ncbi.nlm.nih.gov/pubmed/2549853">PubMed Abstract </a> | <a target=xrefwindow id=d5420e6474 href="https://doi.org/10.1146/annurev.bi.58.070189.002031">Publisher Full Text </a></span></li><li><a name=ref-150 class=n-a></a><span class=label>150. </span>&nbsp;<span class=citation><a name=d5420e6484 class=n-a></a>Fisher GR, Patterson LH: DNA strand breakage by peroxidase-activated mitoxantrone. <i>J Pharm Pharmacol.</i> 1991; <b>43</b>(1): 65–68. <a target=xrefwindow id=d5420e6492 href="http://www.ncbi.nlm.nih.gov/pubmed/1676068">PubMed Abstract </a> | <a target=xrefwindow id=d5420e6495 href="https://doi.org/10.1111/j.2042-7158.1991.tb05455.x">Publisher Full Text </a></span></li><li><a name=ref-151 class=n-a></a><span class=label>151. </span>&nbsp;<span class=citation><a name=d5420e6504 class=n-a></a>De Isabella P, Palumbo M, Sissi C, <i> et al.</i>: Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. <i>Mol Pharmacol.</i> 1995; <b>48</b>(1): 30–38. <a target=xrefwindow id=d5420e6515 href="http://www.ncbi.nlm.nih.gov/pubmed/7623772">PubMed Abstract </a></span></li><li><a name=ref-152 class=n-a></a><span class=label>152. </span>&nbsp;<span class=citation><a name=d5420e6524 class=n-a></a>Errington F, Willmore E, Tilby MJ, <i> et al.</i>: Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation. <i>Mol Pharmacol.</i> 1999; <b>56</b>(6): 1309–1316. <a target=xrefwindow id=d5420e6535 href="http://www.ncbi.nlm.nih.gov/pubmed/10570059">PubMed Abstract </a> | <a target=xrefwindow id=d5420e6538 href="https://doi.org/10.1124/mol.56.6.1309">Publisher Full Text </a></span></li><li><a name=ref-153 class=n-a></a><span class=label>153. </span>&nbsp;<span class=citation><a name=d5420e6547 class=n-a></a>Fox EJ: Mechanism of action of mitoxantrone. <i>Neurology.</i> 2004; <b>63</b>(12 Suppl 6): S15–18. <a target=xrefwindow id=d5420e6555 href="http://www.ncbi.nlm.nih.gov/pubmed/15623664">PubMed Abstract </a> | <a target=xrefwindow id=d5420e6558 href="https://doi.org/10.1212/WNL.63.12_suppl_6.S15">Publisher Full Text </a></span></li><li><a name=ref-154 class=n-a></a><span class=label>154. </span>&nbsp;<span class=citation><a name=d5420e6567 class=n-a></a>Ridge SC, Sloboda AE, McReynolds RA, <i> et al.</i>: Suppression of experimental allergic encephalomyelitis by mitoxantrone. <i>Clin Immunol Immunopathol.</i> 1985; <b>35</b>(1): 35–42. <a target=xrefwindow id=d5420e6578 href="http://www.ncbi.nlm.nih.gov/pubmed/3873302">PubMed Abstract </a> | <a target=xrefwindow id=d5420e6581 href="https://doi.org/10.1016/0090-1229(85)90075-3">Publisher Full Text </a></span></li><li><a name=ref-155 class=n-a></a><span class=label>155. </span>&nbsp;<span class=citation><a name=d5420e6590 class=n-a></a>Edan G, Miller D, Clanet M, <i> et al.</i>: Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. <i>J Neurol Neurosurg Psychiatry.</i> 1997; <b>62</b>(2): 112–118. <a target=xrefwindow id=d5420e6601 href="http://www.ncbi.nlm.nih.gov/pubmed/9048709">PubMed Abstract </a> | <a target=xrefwindow id=d5420e6604 href="https://doi.org/10.1136/jnnp.62.2.112">Publisher Full Text </a> | <a target=xrefwindow id=d5420e6608 href="http://www.ncbi.nlm.nih.gov/pmc/articles/486720">Free Full Text </a></span></li><li><a name=ref-156 class=n-a></a><span class=label>156. </span>&nbsp;<span class=citation><a name=d5420e6618 class=n-a></a>Millefiorini E, Gasperini C, Pozzilli C, <i> et al.</i>: Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. <i>J Neurol.</i> 1997; <b>244</b>(3): 153–159. <a target=xrefwindow id=d5420e6629 href="http://www.ncbi.nlm.nih.gov/pubmed/9050955">PubMed Abstract </a> | <a target=xrefwindow id=d5420e6632 href="https://doi.org/10.1007/s004150050066">Publisher Full Text </a></span></li><li><a name=ref-157 class=n-a></a><span class=label>157. </span>&nbsp;<span class=citation><a name=d5420e6641 class=n-a></a>Hartung HP, Gonsette R, König N, <i> et al.</i>: Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. <i>Lancet.</i> 2002; <b>360</b>(9350): 2018–2025. <a target=xrefwindow id=d5420e6652 href="http://www.ncbi.nlm.nih.gov/pubmed/12504397">PubMed Abstract </a> | <a target=xrefwindow id=d5420e6655 href="https://doi.org/10.1016/S0140-6736(02)12023-X">Publisher Full Text </a></span></li><li><a name=ref-158 class=n-a></a><span class=label>158. </span>&nbsp;<span class=citation><a name=d5420e6664 class=n-a></a>Hande KR: Clinical applications of anticancer drugs targeted to topoisomerase II. <i>Biochim Biophys Acta.</i> 1998; <b>1400</b>(1–3): 173–184. <a target=xrefwindow id=d5420e6672 href="http://www.ncbi.nlm.nih.gov/pubmed/9748560">PubMed Abstract </a> | <a target=xrefwindow id=d5420e6675 href="https://doi.org/10.1016/S0167-4781(98)00134-1">Publisher Full Text </a></span></li><li><a name=ref-159 class=n-a></a><span class=label>159. </span>&nbsp;<span class=citation><a name=d5420e6684 class=n-a></a>Teitelbaum D, Arnon R, Sela M: Copolymer 1: from basic research to clinical application. <i>Cell Mol Life Sci.</i> 1997; <b>53</b>(1): 24–28. <a target=xrefwindow id=d5420e6692 href="http://www.ncbi.nlm.nih.gov/pubmed/9117994">PubMed Abstract </a></span></li><li><a name=ref-160 class=n-a></a><span class=label>160. </span>&nbsp;<span class=citation><a name=d5420e6701 class=n-a></a>La Mantia L, Munari LM, Lovati R: Glatiramer acetate for multiple sclerosis. <i>Cochrane Database Syst Rev.</i> 2010; (5): CD004678. <a target=xrefwindow id=d5420e6706 href="http://www.ncbi.nlm.nih.gov/pubmed/20464733">PubMed Abstract </a> | <a target=xrefwindow id=d5420e6709 href="https://doi.org/10.1002/14651858.CD004678.pub2">Publisher Full Text </a></span></li><li><a name=ref-161 class=n-a></a><span class=label>161. </span>&nbsp;<span class=citation><a name=d5420e6718 class=n-a></a>Rovituso DM, Duffy CE, Schroeter M, <i> et al.</i>: The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients. <i>Sci Rep.</i> 2015; <b>5</b>; 14265. <a target=xrefwindow id=d5420e6729 href="http://www.ncbi.nlm.nih.gov/pubmed/26387426">PubMed Abstract </a> | <a target=xrefwindow id=d5420e6732 href="https://doi.org/10.1038/srep14265">Publisher Full Text </a> | <a target=xrefwindow id=d5420e6736 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4585696">Free Full Text </a></span></li><li><a name=ref-162 class=n-a></a><span class=label>162. </span>&nbsp;<span class=citation><a name=d5420e6746 class=n-a></a>Pharmaceuticals I: New Data from IONIS-HTT Rx Phase 1/2 Study Demonstrates Correlation Between Reduction of Disease-causing Protein and Improvement in Clinical Measures of Huntington's Disease. In First drug to demonstrate lowering of mutant huntingtin, the disease-causing protein, in people with Huntington's disease. Carlsbad, CA. 2018. <a target=xrefwindow id=d5420e6748 href="http://ir.ionispharma.com/node/23661/pdf">Reference Source</a></span></li><li><a name=ref-163 class=n-a></a><span class=label>163. </span>&nbsp;<span class=citation><a name=d5420e6757 class=n-a></a>Sevastou I, Pryce G, Baker D, <i> et al.</i>: Characterisation of Transcriptional Changes in the Spinal Cord of the Progressive Experimental Autoimmune Encephalomyelitis Biozzi ABH Mouse Model by RNA Sequencing. <i>PLoS One.</i> 2016; <b>11</b>(6): e0157754. <a target=xrefwindow id=d5420e6768 href="http://www.ncbi.nlm.nih.gov/pubmed/27355629">PubMed Abstract </a> | <a target=xrefwindow id=d5420e6771 href="https://doi.org/10.1371/journal.pone.0157754">Publisher Full Text </a> | <a target=xrefwindow id=d5420e6775 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4927105">Free Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 01 Mar 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-245&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-245&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> The Wolfson Institute for Biomedical Research, University College London, Gower Street, London, WC1E 6BT, UK<br/> <sup>2</sup> Department of Pharmacological Sciences, Stony Brook University, Stony Brook, New York, 11794, USA<br/> <p> <div class=margin-bottom> Aaron Gregson <br/> <span>Roles: </span> Data Curation, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Kaitlyn Thompson <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Stella E Tsirka <br/> <span>Roles: </span> Supervision, Writing – Review & Editing </div> <div class=margin-bottom> David L Selwood <br/> <span>Roles: </span> Conceptualization, Formal Analysis, Funding Acquisition, Project Administration, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-245/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 01 Mar 2019, 8:245 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.16495.1">https://doi.org/10.12688/f1000research.16495.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2019 Gregson A <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=18029 data-id=16495 data-downloads="" data-views="" data-scholar="10.12688/f1000research.16495.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-245/v1/pdf?article_uuid=af060bf1-9b4a-467b-9919-0a4331e93ef6" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.16495.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Gregson A, Thompson K, Tsirka SE and Selwood DL. Emerging small-molecule treatments for multiple sclerosis: focus on B cells [version 1; peer review: 2 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):245 (<a href="https://doi.org/10.12688/f1000research.16495.1" target=_blank>https://doi.org/10.12688/f1000research.16495.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=16495 id=mobile-track-article-signin-16495 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/16495?target=/articles/8-245"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=18029 /> <input name=articleId type=hidden value=16495 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Bruce V Taylor</strong>, Menzies Institute for Medical Research, University of Tasmania, Australia </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>David R. Booth</strong>, Centre for Immunology and Allergy Research, Westmead Institute for Medical Research, University of Sydney, Australia </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 01 Mar 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-245&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-245&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=8876-44721></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=46531-44722></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-245/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>01 Mar 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Bruce V Taylor</strong>, Menzies Institute for Medical Research, University of Tasmania, Australia </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>David R. Booth</strong>, Centre for Immunology and Allergy Research, Westmead Institute for Medical Research, University of Sydney, Australia </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-245&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-245/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Emerging small-molecule treatments for multiple...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-245/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-245/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-245/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Gregson A et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-245/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-245",
            templates : {
                twitter : "Emerging small-molecule treatments for multiple sclerosis: focus.... Gregson A et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-245/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Emerging small-molecule treatments for multiple sclerosis: focus on B cells", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Emerging small-molecule treatments for multiple sclerosis: focus on B cells", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/16495/18029")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "18029");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "44721": 0,
                           "44722": 2,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "c7a81d8d-b0fe-40b3-91a2-231778873a09";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-245.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-245.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-245.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-245.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-245.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>